var title_f7_1_7184="Postinfectious GN IF";
var content_f7_1_7184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postinfectious glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy shows granular deposition of complement in the glomerular tuft in postinfectious glomerulonephritis. IgG can also be seen in the same distribution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7184=[""].join("\n");
var outline_f7_1_7184=null;
var title_f7_1_7185="Prenatal ultrasound left renal agenesis";
var content_f7_1_7185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound left renal agenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7185=[""].join("\n");
var outline_f7_1_7185=null;
var title_f7_1_7186="Impetigo of the face";
var content_f7_1_7186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impetigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7186=[""].join("\n");
var outline_f7_1_7186=null;
var title_f7_1_7187="Collodion baby";
var content_f7_1_7187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Collodion baby",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This infant appears encased in a taut, shiny stratum corneum, with underlying generalized erythroderma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7187=[""].join("\n");
var outline_f7_1_7187=null;
var title_f7_1_7188="Plantar foot anatomy";
var content_f7_1_7188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plantar foot anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The path of plantar arteries (red) and nerves (green) to the toes is shown. Each digit is innervated by four digital nerves; the dorsal arteries and nerves are not shown in this figure. In order to achieve a complete anesthetic effect, it is necessary to block all four nerves. For a complete block of the great toe, there are additional branches that come up the dorsal aspect of the great toe that can be missed if anesthetic is only injected laterally and medially.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7188=[""].join("\n");
var outline_f7_1_7188=null;
var title_f7_1_7189="Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information";
var content_f7_1_7189=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"    see \"Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19204?source=see_link\">",
"    see \"Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thymoglobulin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"      see \"Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     IV: (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bone marrow transplantation: 1.5-3 mg/kg/day once daily for 4 consecutive days before transplantation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment of graft-versus-host disease: 1.5 mg/kg/dose once daily or every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal transplantation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction: 1-2 mg/kg/day once daily for 4-5 days initiated at time of transplant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute rejection: 1.5mg/kg/day once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heart/lung transplantation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction: 1-2 mg/kg/day depending on baseline platelet count once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rejection: 2 mg/kg/day once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liver, intestinal, or multivisceral transplant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preconditioning/induction: Pretransplant: 2 mg/kg; postop day 1: 3 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rejection: 1.5 mg/kg/day once daily for 7-14 days based upon biopsy results; maximum dose: 2 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Acute renal transplant rejection: 1.5 mg/kg/day once daily for 7-14 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thymoglobulin&reg;: 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer by slow I.V. infusion over 6-12 hours for the preconditioning/induction dose or over 6 hours for the initial acute rejection treatment dose; infuse over 4 hours for subsequent doses if first dose tolerated. Administer through an in-line filter with pore size of 0.22 microns via central line or high flow vein at a final concentration of 0.5 to 2 mg/mL in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F12996420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Variable (consult detailed reference):",
"     </b>",
"     Heparin, hydrocortisone sodium succinate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vial in refrigerator; protect from light; do not freeze. Allow diluent and contents of vial to reach room temperature prior to reconstitution; reconstituted product is stable for up to 24 hours at room temperature; however, since it contains no preservatives, it should be used immediately following reconstitution; compatible with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; Y-site injection compatible with hydrocortisone sodium succinate and heparin 100 units/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; incompatible with heparin 2 units/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute rejection of renal transplant; used in conjunction with concomitant immunosuppression (FDA approved in adults); has also been used as induction therapy in renal transplant; treatment of myelodysplastic syndrome (MDS); prevention and/or treatment of acute rejection after bone marrow, heart/lung, liver, intestinal, or multivisceral transplantation in conjunction with other immunosuppressive agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9885364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Antithymocyte globulin rabbit (Thymoglobulin&reg;) may be confused with antithymocyte globulin equine (Atgam&reg;)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F136009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, headache, malaise, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, gastritis, gastrointestinal moniliasis, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Antirabbit antibody development, cytomegalovirus infection, herpes simplex infection, oral moniliasis, sepsis, systemic infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, cytokine release syndrome, PTLD, neutropenia, serum sickness (delayed)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to antithymocyte globulin, rabbit proteins, or any component; acute or chronic infection",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infusion may cause fever and chills. Infuse first dose slowly over a minimum of 6 hours into a high flow vein; 1 hour prior to infusion, premedicate with corticosteroids, acetaminophen, and/or an antihistamine to reduce incidence of side effects during infusion. Reduce dose in patients with WBC between 2000-3000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or if the platelet count is between 50,000-75,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Consider discontinuing antithymocyte globulin (rabbit) if WBC &lt;2000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Patients should not be immunized with attenuated live virus vaccines during or shortly after treatment; safety of immunization following therapy has not been studied. Should only be used by physicians experienced in immunosuppressive therapy for the treatment of renal transplant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate laboratory and supportive medical resources must be readily available in the facility for patient management. Anaphylaxis has been reported with the use of antithymocyte globulin (rabbit). Epinephrine, oxygen, and resuscitative equipment should be readily available to treat anaphylaxis. Release of cytokines by activated monocytes and lymphocytes may cause fatal cytokine release syndrome (CRS) during administration of antithymocyte globulin. Rapid infusion rates have been associated with CRS in case reports. Severe or life-threatening symptoms include hypotension, acute respiratory distress syndrome, pulmonary edema, myocardial infarction, and tachycardia; symptoms range from a mild, self-limiting \"flu-like\" reaction to severe, life-threatening reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Thrombocytopenia or neutropenia may result from cross-reactive antibodies and is reversible following dose reduction or discontinuation. Risk of post-transplant lymphoproliferative disease or other malignancies may be increased with prolonged use or overdosage of antithymocyte globulin (rabbit) in association with other immunosuppressants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F639175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F639176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelet count, CBC with differential, lymphocyte count, vital signs during infusion",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Possible mechanism may involve elimination of antigen-reactive T-lymphocytes (killer cells) in peripheral blood or alteration of T-cell function",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1045262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action (T-cell depletion): Within one day",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life: 2-3 days",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiviral therapy should be given prophylactically during antithymocyte globulin (rabbit) use.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Di Filippo S, Boissonnat P, Sassolas F, et al, &ldquo;Rabbit Antithymocyte Globulin as Induction Immunotherapy in Pediatric Heart Transplantation,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2003, 75(3):354-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/1/7189/abstract-text/12589158 /pubmed\" id=\"12589158 \" target=\"_blank\">",
"        12589158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horan JT, Liesveld JL, Fenton P, et al, &ldquo;Hematopoietic Stem Cell Transplantation for Multiply Transfused Patients With Sickle Cell Disease and Thalassemia After Low-Dose Total Body Irradiation, Fludarabine, and Rabbit Anti-thymocyte Globulin,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2005, 35(2):171-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/1/7189/abstract-text/15531901/pubmed\" id=\"15531901\" target=\"_blank\">",
"        15531901",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starzl TE, Murase N, Abu-Elmagd K, et al, &ldquo;Tolerogenic Immunosuppression for Organ Transplantation,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9368):1502-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/1/7189/abstract-text/12737859/pubmed\" id=\"12737859\" target=\"_blank\">",
"        12737859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA and Saenz CA, &ldquo;Physical Compatibility of Antithymocyte Globulin (Rabbit) With Heparin Sodium and Hydrocortisone Sodium Succinate,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2003, 60(16):1650-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/1/7189/abstract-text/12966908/pubmed\" id=\"12966908\" target=\"_blank\">",
"        12966908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13168 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7189=[""].join("\n");
var outline_f7_1_7189=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708632\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045257\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045249\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135985\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135975\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045260\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12996420\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045253\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045259\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9885364\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136009\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045264\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045248\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045247\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298764\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218046\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F639175\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F639176\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045256\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045246\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045262\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045263\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045265\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13168\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13168|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=related_link\">",
"      Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19204?source=related_link\">",
"      Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_1_7190="Complications of spinal cord irradiation";
var content_f7_1_7190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of spinal cord irradiation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7190/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7190/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7190/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7190/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7190/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7190/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/1/7190/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy can cause toxicity to either the central or peripheral nervous system when these structures are included in the treatment field. Nervous system toxicity is usually subdivided into acute (during the course of radiation), early delayed (weeks to three months after radiation), and delayed reaction (more than three months).",
"   </p>",
"   <p>",
"    Several syndromes of radiation injury to the spinal cord have been described, the most prominent of which are a self-limited transient myelopathy and the more serious chronic progressive myelopathy. Other more disabling manifestations of radiation injury, including acute paralysis secondary to ischemia, hemorrhage within the spinal cord, and a lower motor neuron syndrome, are much less common, with only a few case reports in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complications that can occur following irradiation of the spinal cord will be reviewed here. Other relevant topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of cranial irradiation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"       \"Complications of cranial irradiation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complications of cranial stereotactic radiosurgery (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/32/2566?source=see_link\">",
"       \"Complications of cranial stereotactic radiosurgery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complications of irradiation of peripheral nerves (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link\">",
"       \"Complications of peripheral nerve irradiation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY RADIATION-INDUCED MYELOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although acute CNS damage has been reported following acute brain irradiation, there is no clinical or experimental evidence that radiation induces acute spinal cord toxicity. Single doses of up to 100 Gy have been given without acute effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A transient radiation-induced myelopathy may develop two to six months following spinal irradiation. This condition is widely believed to be due to temporary demyelination of the posterior columns of the spinal cord and is not generally a precursor of chronic progressive myelitis.",
"   </p>",
"   <p>",
"    The characteristic manifestation of transient radiation myelopathy is the development of Lhermitte's sign, a nonpainful but unpleasant electric shock-like sensation that shoots down the spine during neck flexion. Increased spinal cord metabolic activity and positive PET imaging have been described in association with Lhermitte's sign [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of Lhermitte's sign is difficult to estimate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In two large observational series in patients with Hodgkin lymphoma and nasopharyngeal cancer, respectively, Lhermitte's signs developed in 4 and 10 percent at a mean of three months after radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Some dose-dependence of radiation to the cervical spinal cord was noted; in one of the reports, symptoms lasted an average of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of Lhermitte's sign in cancer patients includes tumor progression causing spinal cord compression, as well as other treatment complications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    neurotoxicity. Other causes of spinal cord disease that can result in Lhermitte's sign include demyelinating diseases (eg, multiple sclerosis), vitamin B12 deficiency, and structural abnormalities of the spinal canal (eg, cervical spondylosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link\">",
"     \"Neurologic complications of platinum-based chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No active intervention is required other than an explanation and reassurance; the syndrome usually resolves spontaneously over a period of months to a year. If the discomfort is severe,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LATE RADIATION-INDUCED MYELOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed injury to the spinal cord typically is manifested by a chronic, progressive myelopathy. Less commonly, such injury can be manifested as a lower motor neuron syndrome or as a hemorrhagic injury from a radiation induced telangiectasia or cavernous angioma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Progressive myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, chronic progressive myelopathy is an ominous late complication of radiation. Unlike transient myelopathy, it is usually irreversible, and there is no treatment with established benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pathology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of pathologic change can occur in patients with radiation myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The first is damage to white matter that ranges from demyelination, through Wallerian degeneration of axons, to frank necrosis. The second change is in blood vessels that can extend from morphologically intact vessels to fibrinoid necrosis and hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The degree of morphologic derangement does not always correlate with clinical severity of the myelopathy. Symptoms usually reflect the size and location of the lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of radiation myelopathy is incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/11\">",
"     11",
"    </a>",
"    ]. The adult spinal cord contains multi potential stem cells (O-2A) that can differentiate into oligodendroglial cells as well as neuro astrocytes. Both oligodendroglial cells and their precursor O-2A cells can be damaged by radiation, leading to loss of myelin function. Radiation also stimulates astrocytes and microglial cells to produce cytokines. One of these cytokines, vascular endothelial growth factor (VEGF), increases the permeability of spinal cord blood vessels leading to edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/12\">",
"     12",
"    </a>",
"    ]. The role that this and other cytokines play in the damage to blood vessels and cellular structures of the spinal cord is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation myelopathy may begin acutely, but more often the onset is insidious. Paresis, numbness, and sphincter dysfunction developing 6 to 12 months after irradiation are the typical manifestations of progressive radiation-induced myelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the initial signs can be subtle, such as decreased temperature sensation or decreased proprioception. These signs may stabilize or slowly but inexorably progress to lower extremity weakness, foot drop, the Brown-Sequard syndrome, incontinence, hyperreflexia, loss of bowel and bladder function, or complete paresis below the irradiated section of the spinal cord. Rarely, neurologic symptoms remit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other etiologies should be excluded prior to diagnosing chronic radiation myelopathy. The most common cause of myelopathy in cancer patients is disease progression or development of new metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/8\">",
"     8",
"    </a>",
"    ]. The differential diagnosis also includes neurotoxicity caused by chemotherapy, trauma, B12 deficiency, paraneoplastic syndromes, and demyelinating diseases such as multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of radiation myelopathy is usually made clinically and supported by spinal magnetic resonance imaging (MRI). Factors that can help clarify the role of radiation-induced damage include the dose of radiation to the spinal cord and the latency period between radiation and the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initially, an MRI may be normal, but later there is hypointensity on T1 and hyperintensity on T2 and FLAIR sequences, frequently with contrast enhancement. Much later there may be only atrophy without evident signal abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spinal fluid examination is usually not helpful with only an increase in the protein concentration. Evoked potentials may show a spinal conduction velocity block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical neurophysiology\", section on 'Evoked potentials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiation dose-volume effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) study, sponsored by the American Society for Therapeutic Radiology and Oncology (ASTRO) and the American Association of Physicists in Medicine (AAPM), analyzed the literature on the risk of chronic radiation myelopathy as a function of the total dose of radiation, the extent of the spinal cord included in the treatment field, and the size of individual treatment fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key findings from this analysis included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using a conventional fractionation schedule (2 Gy per day) and including the entire cross section of the spinal cord, total doses of 50 Gy, 60 Gy, and 69 Gy were associated with risks of chronic myelopathy of 0.2, 6, and 50 percent, respectively.",
"     </li>",
"     <li>",
"      There is at least partial repair of damage following an initial course of RT. With a recovery period of six months, this appears to increase the overall tolerance of the spinal cord by at least 25 percent.",
"     </li>",
"     <li>",
"      With stereotactic body radiation therapy to a partial section of the spinal cord, the risk of radiation myelopathy with a single fraction of 13 Gy or 20 Gy divided into three fractions was less than 1 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No treatment approach has been shown to be beneficial in patients with chronic progressive radiation myelopathy. Because of the severity of this complication, a variety of approaches have been suggested. Anecdotal evidence has suggested that therapy with hyperbaric oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] or anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/21\">",
"     21",
"    </a>",
"    ] might be useful. In addition, limited experimental evidence in an animal model supports the treatment of radiation myelopathy with high doses of corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/22\">",
"     22",
"    </a>",
"    ]. However, there are inadequate data to predict the likelihood of a clinical response with any of these approaches.",
"   </p>",
"   <p>",
"    In animal models, prophylactic hyperbaric oxygen did not prevent radiation myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/23\">",
"     23",
"    </a>",
"    ], but both magnesium and vitamin E ameliorate lipid peroxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/24\">",
"     24",
"    </a>",
"    ], a biochemical abnormality believed to be related to radiation damage. Growth factors (platelet-derived growth factor, insulin like growth factor 1, vascular endothelial growth factor, basic fibrolast growth factor) appear to prevent or delay radiation myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other late complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lower motor neuron syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lower motor neuron syndrome was originally described after radiation therapy for testicular cancer but this syndrome can follow any radiation therapy involving the lower spinal cord and cauda equina [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Although this was originally thought to reflect damage to anterior horn cells, it is in fact, a radiculopathy rather than a neuronopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/29\">",
"     29",
"    </a>",
"    ]. The disorder follows radiation therapy by 3 to 25 years, after which patients develop slowly progressive weakness of lower extremities with little or no sensory loss and normal, or almost normal, bladder and bowel function. The MRI shows gadolinium enhancement or the roots of the cauda equina. Pathologic changes suggest a vasculopathy of proximal spinal roots with preservation of lower motor neurons within the spinal cord. Many patients remain ambulatory for many years although weakness continues to progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Spinal cord hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage to spinal cord blood vessels can, in rare instances, lead to telangiectasia and even cavernous malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/6\">",
"     6",
"    </a>",
"    ]. As many as 30 years after radiation therapy to the spinal cord, patients can develop acute hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7190/abstract/2,30\">",
"     2,30",
"    </a>",
"    ]. There is usually sudden onset of weakness and sensory change, sometimes associated with pain. The MRI shows evidence of acute hemorrhage. Patients usually recover.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy involving the spinal cord can result both in acute symptoms as well as delayed toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A transient radiation-induced myelopathy may develop in up to 10 percent of patients two to six months following spinal irradiation. This condition, which is manifested by Lhermitte's sign, is self-limited and does not predict for the subsequent development of chronic progressive myelopathy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Early radiation-induced myelopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic progressive myelopathy is an ominous late complication of radiation. Unlike transient myelopathy, it is usually irreversible. Radiation myelopathy is typically manifested by paresis, numbness, and sphincter dysfunction developing 6 to 12 months after irradiation. Symptoms are progressive and there is no established treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Progressive myelopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of chronic myelopathy is proportional to the total radiation dose, anatomic extent of spinal cord irradiation, radiation fraction size, and total radiation dose. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Radiation dose-volume effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lower motor neuron syndrome is a disorder that follows radiation therapy by 3 to 25 years. Patients slowly develop progressive weakness of lower extremities with little or no sensory loss and normal, or almost normal, bladder and bowel function. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Lower motor neuron syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Damage to spinal cord blood vessels can lead to telangiectasia and even cavernous malformations, which can result in an acute hemorrhage. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Spinal cord hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/1\">",
"      Rock JP, Ryu S, Yin FF, et al. The evolving role of stereotactic radiosurgery and stereotactic radiation therapy for patients with spine tumors. J Neurooncol 2004; 69:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/2\">",
"      Allen JC, Miller DC, Budzilovich GN, Epstein FJ. Brain and spinal cord hemorrhage in long-term survivors of malignant pediatric brain tumors: a possible late effect of therapy. Neurology 1991; 41:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/3\">",
"      Tefft M, Mitus A, Schulz MD. Initial high dose irradiation for metastases causing spinal cord compression in children. Am J Roentgenol Radium Ther Nucl Med 1969; 106:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/4\">",
"      Esik O, Csere T, Stefanits K, et al. Increased metabolic activity in the spinal cord of patients with long-standing Lhermitte's sign. Strahlenther Onkol 2003; 179:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/5\">",
"      Fein DA, Marcus RB Jr, Parsons JT, et al. Lhermitte's sign: incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1993; 27:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/6\">",
"      Word JA, Kalokhe UP, Aron BS, Elson HR. Transient radiation myelopathy (Lhermitte's sign) in patients with Hodgkin's disease treated by mantle irradiation. Int J Radiat Oncol Biol Phys 1980; 6:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/7\">",
"      Leung WM, Tsang NM, Chang FT, Lo CJ. Lhermitte's sign among nasopharyngeal cancer patients after radiotherapy. Head Neck 2005; 27:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/8\">",
"      Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995; 31:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/9\">",
"      Okada S, Okeda R. Pathology of radiation myelopathy. Neuropathology 2001; 21:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/10\">",
"      Schultheiss TE, Stephens LC, Maor MH. Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys 1988; 14:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/11\">",
"      Nieder C, Ataman F, Price RE, Ang KK. Radiation myelopathy: new perspective on an old problem. Radiat Oncol Investig 1999; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/12\">",
"      Nordal RA, Nagy A, Pintilie M, Wong CS. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 2004; 10:3342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/13\">",
"      Schultheiss TE, Stephens LC, Peters LJ. Survival in radiation myelopathy. Int J Radiat Oncol Biol Phys 1986; 12:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/14\">",
"      Esik O, Emri M, Csornai M, et al. Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord. J Neurol Sci 1999; 163:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/15\">",
"      Lengyel Z, R&eacute;k&oacute; G, Majt&eacute;nyi K, et al. Autopsy verifies demyelination and lack of vascular damage in partially reversible radiation myelopathy. Spinal Cord 2003; 41:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/16\">",
"      Werner-Wasik M, Yu X, Marks LB, Schultheiss TE. Normal-tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk. Hematol Oncol Clin North Am 2004; 18:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/17\">",
"      Komachi H, Tsuchiya K, Ikeda M, et al. Radiation myelopathy: a clinicopathological study with special reference to correlation between MRI findings and neuropathology. J Neurol Sci 1995; 132:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/18\">",
"      Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010; 76:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/19\">",
"      Calabr&ograve; F, Jinkins JR. MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen. Eur Radiol 2000; 10:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/20\">",
"      Luk KH, Baker DG, Fellows CF. Hyperbaric oxygen after radiation and its effect on the production of radiation myelitis. Int J Radiat Oncol Biol Phys 1978; 4:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/21\">",
"      Glantz MJ, Burger PC, Friedman AH, et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994; 44:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/22\">",
"      Geraci JP, Sun MC, Mariano MS. Amelioration of radiation nephropathy in rats by postirradiation treatment with dexamethasone and/or captopril. Radiat Res 1995; 143:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/23\">",
"      Sminia P, van der Kleij AJ, Carl UM, et al. Prophylactic hyperbaric oxygen treatment and rat spinal cord re-irradiation. Cancer Lett 2003; 191:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/24\">",
"      Peker S, Abacioglu U, Sun I, et al. Prophylactic effects of magnesium and vitamin E in rat spinal cord radiation damage: evaluation based on lipid peroxidation levels. Life Sci 2004; 75:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/25\">",
"      Andratschke NH, Nieder C, Price RE, et al. Potential role of growth factors in diminishing radiation therapy neural tissue injury. Semin Oncol 2005; 32:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/26\">",
"      Esik O, V&ouml;n&ouml;czky K, Lengyel Z, et al. Characteristics of radiogenic lower motor neurone disease, a possible link with a preceding viral infection. Spinal Cord 2004; 42:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/27\">",
"      Feistner H, Weissenborn K, M&uuml;nte TF, et al. Post-irradiation lesions of the caudal roots. Acta Neurol Scand 1989; 80:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/28\">",
"      Tallaksen CM, Jetne V, Foss&aring; S. Postradiation lower motor neuron syndrome--a case report and brief literature review. Acta Oncol 1997; 36:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/29\">",
"      Bowen J, Gregory R, Squier M, Donaghy M. The post-irradiation lower motor neuron syndrome neuronopathy or radiculopathy? Brain 1996; 119 ( Pt 5):1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7190/abstract/30\">",
"      Jabbour P, Gault J, Murk SE, Awad IA. Multiple spinal cavernous malformations with atypical phenotype after prior irradiation: case report. Neurosurgery 2004; 55:1431.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7066 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7190=[""].join("\n");
var outline_f7_1_7190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY RADIATION-INDUCED MYELOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LATE RADIATION-INDUCED MYELOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Progressive myelopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pathology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiation dose-volume effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other late complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lower motor neuron syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Spinal cord hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/32/2566?source=related_link\">",
"      Complications of cranial stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_1_7191="Isoniazid (INH) poisoning";
var content_f7_1_7191=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Isoniazid (INH) poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7191/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7191/contributors\">",
"     Rama B Rao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7191/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7191/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7191/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7191/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7191/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/1/7191/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     Isoniazid",
"    </a>",
"    (INH) is an antibiotic used to treat infection with Mycobacterium tuberculosis (TB). A large minority of the world's population is infected with TB. Although the disease is inactive in the majority, up to 10 percent of these persons may become infectious in their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Many patients who are identified as being at risk of developing active, infectious TB or who suffer from active disease are treated with INH.",
"   </p>",
"   <p>",
"    Acute INH toxicity frequently manifests as altered mental status or seizures. Poisoning may occur with unintentional ingestion in children, suicidal intent, or in patients taking extra tablets to compensate for missed doses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Chronic INH toxicity frequently manifests as peripheral neuropathy or hepatotoxicity, although other chronic conditions are described.",
"   </p>",
"   <p>",
"    The presentation and management of acute INH poisoning will be reviewed here. Chronic INH hepatotoxicity and the clinical use of INH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=see_link\">",
"     \"Isoniazid: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimicrobial activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     Isoniazid",
"    </a>",
"    (INH) is selective for mycobacteria, probably resulting from its ability to inhibit mycolic acid synthesis. This inhibition interferes with cell wall synthesis, producing a bactericidal effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=see_link\">",
"     \"Isoniazid: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    INH toxicity stems from several causes, including deficiencies of pyridoxine (vitamin B6) and gamma amino butyric acid (GABA). INH induces a state of functional pyridoxine deficiency by at least two mechanisms. First, INH metabolites directly attach to and inactivate pyridoxine species. Second, INH inhibits the enzyme pyridoxine phosphokinase; this enzyme is necessary to activate pyridoxine to pyridoxal 5' phosphate, the active cofactor in many \"pyridoxine-dependent\" reactions. Functional pyridoxine deficiency is the likely mechanism of INH-induced peripheral neuropathy.",
"   </p>",
"   <p>",
"    INH may induce a critical deficiency in GABA, an inhibitory neurotransmitter that modifies or suppresses excitatory neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. GABA is produced in a pyridoxine-dependent decarboxylation reaction that is slowed by the functional pyridoxine deficiency induced by INH. In addition, INH inhibits glutamate dehydrogenase, the enzyme which catalyzes the conversion of glutamate to GABA. GABA deficiency may manifest as seizures, particularly in acute overdose.",
"   </p>",
"   <p>",
"    INH metabolites, such as acetylhydrazine, cause idiosyncratic direct hepatocellular toxicity. The mechanisms of chronic INH hepatotoxicity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link&amp;anchor=H11#H11\">",
"     \"Isoniazid hepatotoxicity\", section on 'Mechanism of hepatotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;INH is rapidly absorbed from the gastrointestinal tract. Its volume of distribution is between 0.6 and 1.2",
"    <span class=\"nowrap\">",
"     L/kg.",
"    </span>",
"    INH undergoes hepatic metabolism to hydrazones, as well as acetylation to hydrazine and hydrazides. The rate of acetylation may vary by population and affects the elimination half-life. INH may inhibit hepatic enzymes CYP2C9, 2C19, 3A4, and 2E1. The major route of elimination is via the kidney. The pharmacokinetics of INH are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=see_link&amp;anchor=H5#H5\">",
"     \"Isoniazid: An overview\", section on 'Pharmacokinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF ACUTE TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute INH overdose usually manifests as altered or depressed mental status or seizures, including status epilepticus. Higher ingestion doses (&ge;20",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    increase the likelihood of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/7\">",
"     7",
"    </a>",
"    ]. An acute ingestion as small as 2 g may cause toxicity in some adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, seizures may be discrete and isolated, or in severe overdoses, present as status epilepticus. Seizures most commonly start within 30 minutes of the exposure, but may begin up to two hours later and persist for many hours. The patient may also have an altered or depressed mental status in the absence of seizure activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/6,9-12\">",
"     6,9-12",
"    </a>",
"    ]. Coingestants may alter the time of onset or duration of toxicity.",
"   </p>",
"   <p>",
"    Vital sign abnormalities such as tachycardia, tachypnea, and elevations in temperature may occur as a result of seizure activity. Anoxia and aspiration may also occur. Long-term sequelae include anoxic encephalopathy and dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/13\">",
"     13",
"    </a>",
"    ]. The management of INH-induced seizures is described below (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Seizure management'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF CHRONIC TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hepatotoxicity from INH most commonly occurs within the first eight weeks of therapy. INH-induced hepatotoxicity is defined as an AST elevation of three times the upper limit of normal in a patient with symptoms including nausea, vomiting, abdominal pain, or jaundice, or an AST elevation five times the upper limit of normal in an asymptomatic patient. The diagnosis, management, and monitoring of chronic INH hepatotoxicity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sensory peripheral neuropathy can occur in patients taking INH and may be prevented by administering supplemental pyridoxine. Often, patients complain of bilateral numbness and tingling or burning of upper and lower extremities.",
"   </p>",
"   <p>",
"    Rarely, INH-induced neuropathy may include central features such as ataxia and nystagmus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/14\">",
"     14",
"    </a>",
"    ]. Other reactions to INH therapy have been reported and are listed in the attached table (",
"    <a class=\"graphic graphic_table graphicRef75525 \" href=\"UTD.htm?0/11/187\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without a clear history of INH exposure who present with seizures should undergo a comprehensive evaluation for non-toxicologic causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .) If a toxic ingestion is suspected, other (non-INH) causes of seizures should also be entertained (",
"    <a class=\"graphic graphic_table graphicRef83223 \" href=\"UTD.htm?40/39/41596\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    No focal findings distinguish INH-induced status epilepticus from other types of prolonged seizures. The key difference is that seizures due to INH poisoning are often refractory to treatment with benzodiazepines and are difficult to manage without pyridoxine. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Seizure management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinicians should suspect INH as a possible cause of seizures when the patient or a patient's family member is being treated with INH or has emigrated from an area where tuberculosis infection is endemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic abnormalities in acute INH toxicity relate directly to seizure activity and may include metabolic acidosis (due to lactate production), an elevated creatine kinase, and (later) renal insufficiency from rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/4\">",
"     4",
"    </a>",
"    ]. Therefore, laboratory evaluation should include a basic metabolic profile, serum lactate, and creatine kinase, as well as a pregnancy test in women of childbearing age. INH concentrations are not clinically useful as results may take days or weeks to perform.",
"   </p>",
"   <p>",
"    Additional tests for patients with an intentional overdose also include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any seizure or alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate testing to rule out these common coingestants",
"     </li>",
"     <li>",
"      An electrocardiogram to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACUTE TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should be prepared to establish a definitive airway with an endotracheal tube for patients with coma, seizures, or status epilepticus. Patients with a clinically severe INH overdose are at high risk for aspiration and prolonged hypoxia. Airway management is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a neuromuscular blocking agent is used for intubation, a short-acting drug such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    is preferred. Longer-acting agents may mask seizure activity and should be avoided if possible.",
"   </p>",
"   <p>",
"    During any period of drug-induced paralysis, pupillary response may help to determine the presence of ongoing seizure activity. Pupillary reactivity is not typically affected by nicotinic neuromuscular antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    ). Nonreactive pupils suggest ongoing seizure activity and require therapy with pyridoxine as well as GABA agonist medications, such as benzodiazepines. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Seizure management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data regarding the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) or gastric lavage in INH poisoning. While INH is readily bound by AC, the drug is absorbed rapidly and patients with INH overdose are at high risk for aspiration. Thus, we give AC (1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    by mouth or by nasogastric or orogastric tube) only to patients who present early (within one to two hours) following an acute ingestion. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless the patient is intubated. However, tracheal intubation should not be performed solely for the purpose of giving AC.",
"   </p>",
"   <p>",
"    Gastric lavage is rarely indicated. Patients with evidence of severe toxicity (eg, status epilepticus) who present within one to two hours of ingestion and who are either protecting their airway (uncommon with severe toxicity) or are intubated, are candidates for gastric lavage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993923#H18993923\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Gastric lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whole bowel irrigation is unlikely to empty the bowels prior to the onset of central nervous system toxicity and is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. Syrup of ipecac should be avoided, even in the otherwise asymptomatic patient, since seizures may begin during the induction of emesis, increasing the risk of aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Seizure management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of seizure management in acute INH poisoning is to repair the critical deficiency in the inhibitory neurotransmitter gamma amino butyric acid (GABA). This is accomplished by intravenous (IV) administration of",
"    <strong>",
"     both",
"    </strong>",
"    pyridoxine (to overcome functional pyridoxine deficiency) and a benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ), which potentiates the effects of available GABA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/7-9,15\">",
"     7-9,15",
"    </a>",
"    ]. The use of either agent alone may be inadequate to control seizure activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pyridoxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyridoxine (vitamin B6) binds to INH, repletes stores of pyridoxine and pyridoxal 5' phosphate, and facilitates the production of GABA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. The onset of action is rapid. Patients in status epilepticus refractory to benzodiazepines often stop seizing within minutes of pyridoxine administration. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pharmacology and cellular toxicology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The dose of pyridoxine is 1 g intravenously for every gram of INH ingested. When the quantity of INH ingested is unknown, 5 g IV may be administered to an adult and 70",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 5 g) to a child. The dose can be administered at a rate of 0.5",
"    <span class=\"nowrap\">",
"     g/min,",
"    </span>",
"    and may be repeated in patients with refractory seizure activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/7,8,16,17\">",
"     7,8,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pyridoxine is a water soluble vitamin with a wide therapeutic margin. Acute pyridoxine-induced neuropathy is reported at doses of 1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    a dose unlikely to be required for the management of INH overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines act on the GABA receptor and enhance neuroinhibition.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    may be used to terminate seizure activity from INH poisoning, but may need to be administered repeatedly in escalating doses. In adults, lorazepam 1 to 2 mg IV can be given every five minutes. The dose may be doubled in cases of persistent seizures. In children, lorazepam (0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, up to 2 mg per dose) may be given and repeated as necessary every five minutes. Alternative benzodiazepines may be used if lorazepam is unavailable. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Pediatric considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other sedative hypnotic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultra-short acting barbiturates are useful for intubation and terminating status epilepticus, but these agents do not have a sustained duration of action for controlling seizures. In addition, they can cause hypotension and should be avoided in hypotensive or hypovolemic patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    , a longer acting barbiturate, may be used as adjunctive therapy for patients with persistent seizures or when there is a delay in obtaining pyridoxine. The dose is 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    by slow IV push. Endotracheal intubation is usually required when phenobarbital is combined with other sedative-hypnotic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Phenytoin and fosphenytoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    are unlikely to be efficacious in treating INH-induced seizures and status epilepticus and are not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all the metabolic derangements associated with severe INH toxicity are the result of status epilepticus or refractory seizure activity, which can be associated with lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/7\">",
"     7",
"    </a>",
"    ]. Stopping the seizure activity and providing adequate ventilatory support usually results in rapid reversal of acidemia, since metabolism of the excess lactate regenerates bicarbonate.",
"   </p>",
"   <p>",
"    The appropriate role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    administration in INH toxicity remains unclear. Sodium bicarbonate has been used in severe cases of lactic acidosis from status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/18\">",
"     18",
"    </a>",
"    ]. In general, most physicians would limit the use of sodium bicarbonate to patients with severe metabolic acidemia (arterial pH below 7.10 to 7.15), with the aim being to maintain the pH above 7.15 until the primary process can be reversed. The administration of sodium bicarbonate should",
"    <strong>",
"     not",
"    </strong>",
"    precede treatment with a benzodiazepine and pyridoxine, as the cause of the acidosis will persist despite attempts to correct the pH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Enhanced elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis is generally not indicated in INH poisoning. While hemodialysis may remove INH from the circulation, patients with severe toxicity become symptomatic before it is feasible to perform the procedure. Adequate pyridoxine and benzodiazepine therapy generally obviate the need for hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/7\">",
"     7",
"    </a>",
"    ]. Hemodialysis may be helpful in the rare setting of a massive overdose when adequate pyridoxine is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prolonged coma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with adequate seizure control may develop a persistent coma from INH toxicity or the administration of sedative hypnotic agents. There are reports of supplemental pyridoxine being used to reverse prolonged comas lasting up to 42 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/10\">",
"     10",
"    </a>",
"    ]. The mechanism by which pyridoxine causes such a reversal, remains unclear. Pyridoxine doses of 3 to 5 g in adults (in addition to the initial doses used to treat seizures) were used in these cases. We suggest obtaining consultation with a medical toxicologist when such treatment is considered. (See",
"    <a class=\"local\" href=\"#H11187531\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other causes of persistent coma, such as a closed head injury sustained during seizure activity, hypoglycemia, or coingestants, should be considered simultaneously when considering treatment with additional pyridoxine. Once a patient regains consciousness from a prolonged coma, they should be assessed for injuries associated with the initial seizure. Spinal compression fractures are among the injuries that have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia is generally the result of seizure activity and should spontaneously resolve once seizures are controlled. Antipyretics are unnecessary. Causes other than seizure (eg, aspiration pneumonia) should be investigated in patients with a delayed presentation of hyperthermia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of INH overdose is fundamentally the same in children and adults with the exception of medication dosing. Therapeutic dosing for children with INH induced seizures is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      &ndash; 0.05 to 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously (IV); doses may be repeated every five minutes up to 10 mg total over 20 minutes.",
"     </li>",
"     <li>",
"      Pyridoxine &ndash; 70",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, up to 5 g in a child, with supplemental dosing if this is ineffective. A dose of 1 gram pyridoxine per gram of INH ingested can be used (and may be necessary) if the quantity of INH ingested is known [",
"      <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum INH concentrations are not typically indicated for clinical management but may be used with infant ingestions to confirm the etiology of seizures after the patient recovers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7191/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When intravenous access is delayed, as may be the case in infants and toddlers, rectal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    may be administered. The dose in younger children is 0.5",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Intraosseous access is a viable alternative when IV access cannot be obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link\">",
"     \"Intraosseous infusion\"",
"    </a>",
"    .) Oral pyridoxine per nasogastric tube may be used initially (provided the airway is secure), but IV pyridoxine should be administered as soon as IV access is established.",
"   </p>",
"   <p>",
"    The circumstance of any pediatric exposure should be carefully evaluated to ensure that the safety of the child (and other children who live where the exposure occurred) is adequately addressed. A child prescribed INH who presents with seizures should have their prescription bottles carefully inspected for dosing errors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unintentional exposures who remain asymptomatic with normal vital signs for six hours are unlikely to manifest delayed toxicity and may be medically cleared for discharge.",
"   </p>",
"   <p>",
"    Patients with a suicidal overdose who present with seizures should be admitted to an intensive care unit for treatment and observation.",
"   </p>",
"   <p>",
"    Patients who are symptomatic from taking extra doses of INH, with the intent of compensating for missed doses, may require admission. The clinician may use discretion if the patient had one seizure that responds to dose-appropriate treatment and then returns to baseline function. Such a patient may be a candidate for discharge if the following conditions are met over a six hour observation period:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The history of an isolated, accidental overdose is verified.",
"     </li>",
"     <li>",
"      The patient remains hemodynamically stable.",
"     </li>",
"     <li>",
"      The patient remains free of any seizure activity or alterations in mental status, and maintains a normal level of function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, should the clinician harbor any doubts about the patient's medical condition or whether there is adequate assistance at home, the patient should be admitted for observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11187531\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      (INH) is an antibiotic widely used to treat infection with Mycobacterium tuberculosis (TB). INH toxicity stems from several causes, including deficiencies of pyridoxine (vitamin B6) and gamma amino butyric acid (GABA). These deficiencies can cause seizures that do not respond to standard therapy. INH is rapidly absorbed from the gastrointestinal tract. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute INH overdose usually manifests as altered or depressed mental status or seizures, including status epilepticus. Seizures may be discrete and isolated, or in severe overdoses, present as status epilepticus. Seizures most commonly start within 30 minutes of the exposure, but may begin up to two hours later and persist for many hours. Hepatotoxicity and peripheral neuropathy are potential chronic effects of INH treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of acute toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients without a clear history of INH exposure who present with seizures should undergo a comprehensive evaluation for non-toxicologic causes. Clinicians should suspect INH as a possible cause of seizures when the patient or a patient's family member is being treated with INH or has emigrated from an area where tuberculosis infection is endemic, or when seizures fail to respond to appropriate benzodiazepine therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic abnormalities in acute INH toxicity relate directly to seizure activity. Laboratory evaluation should include a basic metabolic profile, serum lactate, and creatine kinase, as well as a pregnancy test in women of childbearing age. INH concentrations are not clinically useful. Standard testing for coingestants should be performed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should be prepared to establish a definitive airway for patients with coma, seizures, or status epilepticus. Patients with a clinically severe INH overdose are at high risk for aspiration and prolonged hypoxia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Airway management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We give AC (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      by mouth or by nasogastric or orogastric tube) only to patients who present early (within one to two hours) following an acute ingestion. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless the patient is intubated. However, tracheal intubation should not be performed solely for the purpose of giving AC. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with pyridoxine for all patients with seizures from acute INH poisoning (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In addition, these patients should receive standard seizure treatment with a benzodiazepine. The use of either agent alone may be inadequate to control seizure activity. The dose of pyridoxine is 1 g IV for every gram of INH ingested. When the quantity of INH ingested is unknown, 5 g IV may be administered to an adult and 70",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 5 g) to a child; additional pyridoxine may be needed. For a benzodiazepine, we give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      1 to 2 mg IV every five minutes. In children, lorazepam (0.05 to 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, up to 2 mg per dose) may be given and repeated as necessary every five minutes. Alternative benzodiazepines may be used if lorazepam is unavailable. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Seizure management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. www.Who.int/mediacentre/factsheets/fs104/en/index.html (Accessed on July 18, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Trends in tuberculosis--United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/3\">",
"      American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/4\">",
"      Panganiban LR, Makalinao IR, Corte-Maramba NP. Rhabdomyolysis in isoniazid poisoning. J Toxicol Clin Toxicol 2001; 39:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/5\">",
"      Wilcox WD, Hacker YE, Geller RJ. Acute isoniazid overdose in a compliant adolescent patient. Clin Pediatr (Phila) 1996; 35:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/6\">",
"      Sullivan EA, Geoffroy P, Weisman R, et al. Isoniazid poisonings in New York City. J Emerg Med 1998; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/7\">",
"      Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. Eur J Emerg Med 2005; 12:78.",
"     </a>",
"    </li>",
"    <li>",
"     Howland, MA. Pyridoxide. In: Goldfrank's Toxicologic Emergencies, 9th, Nelson, L, Lewin, N, Howland, MA, et al (Eds), McGraw-Hill, New York 2010. p.845.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/9\">",
"      Brent, J, Kulig, K, Rumack, BH. The paradoxical anticonvulsive and awakening effect of high-dose pyridoxine treatment for isoniazid intoxication-Reply. Arch Intern Med 1992; 152:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/10\">",
"      Brent J, Vo N, Kulig K, Rumack BH. Reversal of prolonged isoniazid-induced coma by pyridoxine. Arch Intern Med 1990; 150:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/11\">",
"      Shah BR, Santucci K, Sinert R, Steiner P. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics 1995; 95:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/12\">",
"      Ehsan T, Malkoff MD. Acute isoniazid poisoning simulating meningoencephalitis. Neurology 1995; 45:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/13\">",
"      McLay RN, Drake A, Rayner T. Persisting dementia after isoniazid overdose. J Neuropsychiatry Clin Neurosci 2005; 17:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/14\">",
"      Lewin PK, McGreal D. Isoniazid toxicity with cerebellar ataxia in a child. CMAJ 1993; 148:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/15\">",
"      Chin L, Sievers ML, Herrier RN, Picchioni AL. Potentiation of pyridoxine by depressants and anticonvulsants in the treatment of acute isoniazid intoxication in dogs. Toxicol Appl Pharmacol 1981; 58:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/16\">",
"      Morrow LE, Wear RE, Schuller D, Malesker M. Acute isoniazid toxicity and the need for adequate pyridoxine supplies. Pharmacotherapy 2006; 26:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/17\">",
"      Burda AM, Sigg T, Haque D, Bardsley CH. Inadequate pyridoxine stock and its effect on patient outcome. Am J Ther 2007; 14:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/18\">",
"      Black LE, Ros SP. Complete recovery from severe metabolic acidosis associated with isoniazid poisoning in a young boy. Pediatr Emerg Care 1989; 5:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/19\">",
"      Kalaci A, Duru M, Karazincir S, et al. Thoracic spine compression fracture during isoniazid-induced seizures: case report. Pediatr Emerg Care 2008; 24:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7191/abstract/20\">",
"      Minns AB, Ghafouri N, Clark RF. Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy. Pediatr Emerg Care 2010; 26:380.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 316 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7191=[""].join("\n");
var outline_f7_1_7191=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF ACUTE TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES OF CHRONIC TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT OF ACUTE TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Seizure management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pyridoxine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other sedative hypnotic medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Phenytoin and fosphenytoin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Enhanced elimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prolonged coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11187531\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/316|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/11/187\" title=\"table 1\">",
"      INH reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/39/41596\" title=\"table 2\">",
"      Partial list of seizure-inducing toxins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=related_link\">",
"      Isoniazid: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_1_7192="Epidemiology, risk factors, and pathogenesis of urinary incontinence";
var content_f7_1_7192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7192/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7192/contributors\">",
"     Catherine E DuBeau, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7192/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7192/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7192/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7192/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/1/7192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence is the complaint of involuntary loss of urine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/1\">",
"     1",
"    </a>",
"    ]. While a specific etiologic cause of urinary incontinence is often identifiable in younger persons, a multifactorial syndrome is more likely in older persons. In the older population, urinary incontinence may represent the intersection of neuro-urinary pathology, age-related factors, comorbid conditions, medications, and functional and cognitive impairments [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/2\">",
"     2",
"    </a>",
"    ]. Providers may underestimate the prevalence of incontinence in their patients because at least one-half of people with incontinence do not report the problem to healthcare personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/3\">",
"     3",
"    </a>",
"    ]. Routinely asking patients over 65 years of age about their symptoms and urinary habits is recommended because of the significant morbidity and quality of life impact associated with urinary incontinence in this group.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, risk factors, and pathogenesis of urinary incontinence, primarily in women. Urinary incontinence in men, as well as the clinical presentation, diagnosis, and treatment in women, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41737?source=see_link\">",
"     \"Urinary incontinence in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of urinary incontinence in women, using the inclusive definition of any leakage at least once in the past year, ranges from 25 to 51 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Weekly urine leakage was reported in 10 percent of women in an ethnically diverse urban population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of incontinence increases with age. In a large representative US survey of nonpregnant women, moderate or severe urinary incontinence (at least weekly or monthly leakage of more than just drops) was reported to affect 7 percent of women ages 20 to 39, 17 percent ages 40 to 59, 23 percent ages 60 to 79, and 32 percent age &ge; 80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/7\">",
"     7",
"    </a>",
"    ]. In another survey, the prevalence of any urinary incontinence in nulligravid young women (aged 16 to 30 years) was somewhat higher at 12.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of urinary incontinence is significantly higher for individuals living in nursing homes, compared to community settings, with rates ranging from 43 to 77 percent (median 58 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/9\">",
"     9",
"    </a>",
"    ]. Prevalence rates in a US survey were 60 to 78 percent for women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/10\">",
"     10",
"    </a>",
"    ]. Six to 10 percent of nursing home admissions in the US are attributable to urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/11\">",
"     11",
"    </a>",
"    ]. Nursing home residents with dementia are just as likely to have stress incontinence and bladder outlet obstruction as cognitively intact residents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary incontinence is common in persons with cognitive impairment. The presence of cognitive impairment, especially in frailer older persons, is associated with a 1.5- to 3.5-fold increase in the risk of urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/13\">",
"     13",
"    </a>",
"    ]. The risk of incontinence increases with moderate and severe dementia, after controlling for age, residence, and ambulatory function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/14\">",
"     14",
"    </a>",
"    ]. Older women &ge;65 years of age with cognitive decline are more likely to report incontinence that interferes with activities, but not likely to more frequent incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/15\">",
"     15",
"    </a>",
"    ]. The association between cognitive impairment and incontinence is in part mediated by functional impairment and disability [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of urinary incontinence by race or ethnicity in women has been variably reported. Prevalence was higher in non-Hispanic white women compared to African American women in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/6,17\">",
"     6,17",
"    </a>",
"    ], higher in white and Mexican American women compared to black women in another [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/18\">",
"     18",
"    </a>",
"    ], and did not differ between",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    groups in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/7,19\">",
"     7,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary incontinence is common during pregnancy, affecting 30 to 60 percent of pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/20\">",
"     20",
"    </a>",
"    ]. In the postpartum period, approximately 6 to 35 percent of women report incontinence; leakage is mild (drops) in about half of women and resolves in the postpartum period in 70 percent of those affected [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of incontinence (frequency and volume) also increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/21\">",
"     21",
"    </a>",
"    ]. One third of women in the Nurse's Health Study (aged 54 to 79 years) who reported urine leakage once monthly at baseline progressed to leaking at least once a week over two-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/22\">",
"     22",
"    </a>",
"    ]. It is likely that a large majority of these women did not seek or receive treatment. Daily incontinence was reported in 12 percent of US women between the ages of 60 and 64 years, and in 21 percent of women 85 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of specific types of incontinence is difficult to estimate because of wide variation in definitions. In general, about half of affected women have stress incontinence, with mixed stress and urge next common, and urge incontinence least common [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/13\">",
"     13",
"    </a>",
"    ]. These proportions change with age, with urge incontinence becoming more common [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bother, in addition to symptoms related to overactive bladder (OAB), were evaluated using a screening tool distributed by mailed survey to a representative sample in the United States (163,000 respondents; 55 percent female, 22 percent 65 years or older) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/24\">",
"     24",
"    </a>",
"    ]. Significant bother was reported by 27 percent, of whom less than half (46 percent) had discussed their symptoms with a clinician, 22 percent had used prescription medication for OAB at some time, and 8 percent were currently on treatment.",
"   </p>",
"   <p>",
"    A subset of patients with overactive bladder symptoms have urgency, frequency, and nocturia, but do not have urge incontinence, a condition referred to as \"OAB-dry.\" In a European survey, which used a definition of OAB-dry as &gt;4 episodes of urgency in the previous 4 weeks and either frequency &gt;8 times per day or \"coping behaviors\" to control bladder symptoms, only 36 percent of patients with urgency and frequency had urge incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/25\">",
"     25",
"    </a>",
"    ]. In one telephone survey of US adults over age 18 years, OAB-dry was reported in 7.6 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/26\">",
"     26",
"    </a>",
"    ]; greater female prevalence (15.6 percent) was found in a Canadian survey [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/27\">",
"     27",
"    </a>",
"    ]. The natural history of OAB-dry symptoms is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Costs to society",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total urinary incontinence-related costs in the US were nearly $20 billion in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/28\">",
"     28",
"    </a>",
"    ]. Cost distribution was as follows: 56 percent consequence costs (eg, nursing home admissions) and loss of productivity, 32 percent treatment costs, 9 percent routine care costs, and 3 percent diagnostic costs. These estimated costs do not include intangible costs such as effects on quality of life. Costs in the US have nearly doubled for older men and women in the past decade [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A study of 655 community-dwelling women (mean age 52 years) electing surgical treatment for stress incontinence found that before surgical intervention, the annual mean cost of self-expenditure for incontinence management was $751, accounting for almost 1 percent of the median annual household income [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/31\">",
"     31",
"    </a>",
"    ]. Another study in patients with incontinence of any type found costs higher for urge compared with stress incontinence and higher for African American compared with white women; annualized expenditures for patients with severe incontinence was $900 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical morbidity associated with urinary incontinence includes perineal candida infection; cellulitis and pressure ulcers from constant skin moisture and irritation, urinary tract infections and urosepsis from urinary retention and indwelling catheters, falls and fractures from slipping on urine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/33\">",
"     33",
"    </a>",
"    ], and sleep interruption and deprivation from nocturia (or urinary incontinence care in institutionalized persons). Psychological morbidity includes poor self esteem, social withdrawal, depression, and sexual dysfunction secondary to the associated embarrassment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/34\">",
"     34",
"    </a>",
"    ]. Among the frailer elderly, incontinence contributes to frailty, increases caregiver burden, and contributes to decisions to place individuals in nursing homes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/2\">",
"     2",
"    </a>",
"    ]. Urinary incontinence is not associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Quality of life impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence may greatly influence a number of areas that are important to quality of life including physical, social, and role functions; mental health; and general health perceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/34\">",
"     34",
"    </a>",
"    ]. In older persons, the impact appears greatest in the area of coping with embarrassment with subsequent activity interference, rather than directly precluding activities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary incontinence has been demonstrated to adversely impact quality of life even in frail nursing home residents, suggesting a need to improve continence care in the nursing home setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND CONTRIBUTING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Established risk factors for urinary incontinence in women are childbearing, obesity, other urinary symptoms, and functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/13,38,39\">",
"     13,38,39",
"    </a>",
"    ]. The impact of these risk factors changes with age: childbearing predominates in younger women, and functional impairment in older women.",
"   </p>",
"   <p>",
"    Other suggested risk factors include a history of childhood enuresis, high impact physical activities, diabetes, stroke, depression, functional impairment, fecal incontinence, vaginal delivery, episiotomy, estrogen depletion, genitourinary surgery (eg, hysterectomy) and radiation (",
"    <a class=\"graphic graphic_table graphicRef81958 \" href=\"UTD.htm?21/18/21805\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/1,40-45\">",
"     1,40-45",
"    </a>",
"    ]. There may also be a familial predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Non-Hispanic white women have higher rates of incontinence than non-Hispanic Black and Hispanic women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of comorbid conditions, medications, and functional factors may cause or worsen incontinence (",
"    <a class=\"graphic graphic_table graphicRef80413 \" href=\"UTD.htm?3/11/3261\">",
"     table 2",
"    </a>",
"    ). The role of alcohol and asymptomatic bacteriuria has not been proven.",
"   </p>",
"   <p>",
"    As noted above, age is a risk factor for urinary incontinence in both women and men. Urinary incontinence shares common risk factors with other geriatric syndromes in older persons (eg, falls and functional dependence), including lower and upper extremity weakness, sensory and affective impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/48\">",
"     48",
"    </a>",
"    ], and radiological evidence of white matter signal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/49\">",
"     49",
"    </a>",
"    ] suggesting common etiological pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/2\">",
"     2",
"    </a>",
"    ]. Older individuals frequently have comorbid conditions and take medications that can impair continence by direct effects upon lower urinary tract function, alteration in volume status and urine excretion, cognitive impairment, and by impairment of the functional ability to toilet [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/2\">",
"     2",
"    </a>",
"    ]. The institutionalized elderly with incontinence are more likely than their continent peers to have impaired mobility, dementia, delirium, and receive psychoactive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continence depends upon both intact micturition physiology (including lower urinary tract, pelvic, and neurologic components) and an intact functional ability to toilet oneself. Successful toileting depends upon ready access to toilet facilities, the motivation to maintain dryness, sufficient mobility and manual dexterity, and the cognitive ability to recognize and react appropriately to sensations of bladder filling. As discussed above, the presence of urinary incontinence in older persons frequently reflects multidimensional and multiple impairments.",
"   </p>",
"   <p>",
"    Whether OAB-dry is a separate pathological entity from urge urinary incontinence, or is part of a continuum, is not known. As with urge incontinence, the OAB-dry symptom complex could arise from a combination of specific pathophysiological changes and factors outside the lower urinary tract.",
"   </p>",
"   <p>",
"    Age-related changes in the lower urinary tract may predispose some older individuals to urinary incontinence. However, many persons with these changes remain asymptomatic and continent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/50\">",
"     50",
"    </a>",
"    ]. Thus, age-related factors do not necessarily cause voiding problems, and voiding symptoms and urinary incontinence are never a part of \"normal\" aging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Normal micturition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential elements involved in the storage and emptying cycles of normal micturition include inhibition and contraction of detrusor smooth muscle, afferent signalling from the urothelium, contraction and relaxation of the smooth and striated sphincter muscles, and the central, peripheral, and autonomic nervous systems.",
"   </p>",
"   <p>",
"    In general, urine storage occurs because afferent signals from bladder filling activate sympathetic pathways in the hypogastric and pudendal nerves, which lead to stimulation (contraction) of the smooth and striated sphincters, and also inhibit detrusor contraction. High cortical centers are activated, especially in the pre-frontal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/51\">",
"     51",
"    </a>",
"    ], and stimulate the storage center in the rostral pons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/52\">",
"     52",
"    </a>",
"    ]. When further bladder filling leads to increased",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    qualitatively different afferent signalling from the bladder, spinobulbospinal reflex pathways are carried via the pelvic nerve and spinal cord to the pontine micturition center, which in turn activates parasympathetic pathways that cause bladder contraction and inhibit sympathetic and pudendal contraction of the sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The right anterior cingulate gyrus appears to play a major role in control of urgency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/51\">",
"     51",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef62790 \" href=\"UTD.htm?22/28/22976\">",
"     figure 1",
"    </a>",
"    ). Urine storage is facilitated by a fascial and muscular urethral support \"hammock\" that compresses the urethra when there is increased abdominal pressure or when the pelvic muscles are contracted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The parasympathetic stimulation of detrusor contraction occurs via cholinergic muscarinic receptors in detrusor smooth muscle. Urethral smooth muscle contraction occurs chiefly via stimulation of alpha-adrenerigic receptors.",
"   </p>",
"   <p>",
"    In addition, a variety of neurotransmitter systems in the urothelial lining of the bladder and in bladder interstitial cells likely play a role in mediating bladder contraction and relaxation via afferent signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/54\">",
"     54",
"    </a>",
"    ]. The complex coordinated series of central, peripheral, and autonomic neuronal signals results in socially appropriate and effective voiding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Age-related changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several physiologic changes occur in the lower urinary tract of both continent and incontinent older persons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of involuntary (uninhibited) detrusor contractions, or detrusor overactivity, increases with aging. Detrusor overactivity has been found in 21 percent of healthy, continent, community-dwelling elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Detrusor contractility decreases, leading to a decrease in urinary flow rate in both older men and women, and a modest increase in postvoiding residual (to &lt; 50 ml). The cause of this underactivity may not be the detrusor muscle, but impaired urothelial sensory function [",
"      <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/55\">",
"       55",
"      </a>",
"      ]. Severe detrusor underactivity can cause overflow urinary incontinence and retention, and occurs in about 5 to 10 percent of older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/56\">",
"       56",
"      </a>",
"      ]. Etiologies of detrusor underactivity include smooth muscle damage, fibrosis, low estrogen state, aging, peripheral neuropathy (due to diabetes mellitus, vitamin B12 deficiency, alcoholism), and damage to the spinal detrusor efferents by disc herniation, spinal stenosis, tumor, or congenital abnormalities.",
"     </li>",
"     <li>",
"      Urethral closure pressure decreases in women, possibly reflecting observed age-related decreases in urethral striated muscle (seen in both women and men) and urethral blood flow. Urethral sensation, on the other hand, appears to increase in older women.",
"     </li>",
"     <li>",
"      Low estrogen levels after menopause result in atrophy of the superficial and intermediate layers of the urethral mucosal epithelium with subsequent atrophic urethritis, diminished urethral mucosal seal, loss of compliance, and possible irritation. The relationship of these changes to urinary incontinence remains uncertain, especially in light of the WHI and other trials which found that estrogen replacement therapy increased urinary incontinence [",
"      <a class=\"abstract\" href=\"UTD.htm?7/1/7192/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The diurnal pattern of fluid excretion may shift towards increased volume of urine excreted later in the day, leading to nocturia. Possible causes include peripheral edema due to comorbid diseases and medications (eg, congestive heart failure, hypothyroidism, venous insufficiency,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ), age-related changes in the renal filtration rate, and alterations in diurnal levels of antidiuretic hormone and atrial natriuretic factor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=see_link\">",
"       \"Nocturia: Clinical presentation, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes predispose to urinary incontinence but, as previously mentioned, are not alone sufficient to cause the problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=see_link\">",
"       \"Patient information: Urinary incontinence (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=see_link\">",
"       \"Patient information: Neurogenic bladder in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=see_link\">",
"       \"Patient information: Treatments for urge incontinence in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"       \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"       \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary incontinence affects 30 to 50 percent of women over 60 years of age. At least one-half of incontinent patients do not spontaneously report their problem to healthcare providers, and patients over 65 years of age should be routinely questioned about their voiding habits. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stress incontinence accounts for about half of the incontinence in women. Urge incontinence becomes more prevalent with increasing age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Costs of urinary incontinence, about $20 billion in the US in 2000, have nearly doubled in the past decade. Urinary incontinence has a major impact on quality of life and is associated with urinary infections, skin integrity, falls with fractures, and nursing home placement. Urinary incontinence does not contribute to increased mortality. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Costs to society'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major risk factors for incontinence are increasing age, parity, multiple comorbid diseases, medications, and functional impairment. It should not be assumed that incontinence is inevitable in a patient with multiple risk factors. Treatable causes should always be sought, including assuring that the patient has access to and sufficient mobility for toileting. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors and contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aging leads to many factors that predispose to urinary incontinence: detrusor overactivity, decreased bladder contractility, decreased flow rate, increased post void residual volume, and change in diurnal fluid excretion. These factors do not necessarily result in urinary incontinence, and incontinence is not a part of \"normal\" aging. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Age-related changes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/1\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     DuBeau CE, Kuchel GA, Johnson T, et al.. Incontinence in the frail elderly. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications Ltd, Paris 2009. p.961.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/3\">",
"      Branch LG, Walker LA, Wetle TT, et al. Urinary incontinence knowledge among community-dwelling people 65 years of age and older. J Am Geriatr Soc 1994; 42:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/4\">",
"      Buckley BS, Lapitan MC, Epidemiology Committee of the Fourth International Consultation on Incontinence, Paris, 2008. Prevalence of urinary incontinence in men, women, and children--current evidence: findings of the Fourth International Consultation on Incontinence. Urology 2010; 76:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/5\">",
"      Markland AD, Richter HE, Fwu CW, et al. Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol 2011; 186:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/6\">",
"      Tennstedt SL, Link CL, Steers WD, McKinlay JB. Prevalence of and risk factors for urine leakage in a racially and ethnically diverse population of adults: the Boston Area Community Health (BACH) Survey. Am J Epidemiol 2008; 167:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/7\">",
"      Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA 2008; 300:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/8\">",
"      O'Halloran T, Bell RJ, Robinson PJ, Davis SR. Urinary incontinence in young nulligravid women: a cross-sectional analysis. Ann Intern Med 2012; 157:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/9\">",
"      Offermans MP, Du Moulin MF, Hamers JP, et al. Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. Neurourol Urodyn 2009; 28:288.",
"     </a>",
"    </li>",
"    <li>",
"     Sayhoun N, Pratt L, Lentzner H, et al. The Changing Profile of Nursing Home Residents: 1985-1997. Centers for Disease Control and Prevention, National Center for Health Statistics, 2001. Available at www.cdc.gov/nchs/data/ahcd/agingtrends/04nursin.pdf (Accessed on September 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/11\">",
"      Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. Value Health 2006; 9:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/12\">",
"      Resnick NM, Yalla SV, Laurino E. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 1989; 320:1.",
"     </a>",
"    </li>",
"    <li>",
"     Milson I, Altman D, Lapitan, et al.. Epidemiology of urinary and faecal incontinence and pelvic organ prolapse. In: Incontinence, 4th ed., Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publications Ltd., Plymouth, UK 2009. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/14\">",
"      Hunskaar S, Ostbye T, Borrie MJ. Prevalence of urinary incontinence in elderly Canadians with special emphasis on the association with dementia, ambulatory function, and institutionalization. Norwegian J Epidemiol 1988; 8:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/15\">",
"      Huang AJ, Brown JS, Thom DH, et al. Urinary incontinence in older community-dwelling women: the role of cognitive and physical function decline. Obstet Gynecol 2007; 109:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/16\">",
"      Cigolle CT, Langa KM, Kabeto MU, et al. Geriatric conditions and disability: the Health and Retirement Study. Ann Intern Med 2007; 147:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/17\">",
"      Brown JS, Nyberg LM, Kusek JW, et al. Proceedings of the National Institute of Diabetes and Digestive and Kidney Diseases International Symposium on Epidemiologic Issues in Urinary Incontinence in Women. Am J Obstet Gynecol 2003; 188:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/18\">",
"      Dooley Y, Kenton K, Cao G, et al. Urinary incontinence prevalence: results from the National Health and Nutrition Examination Survey. J Urol 2008; 179:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/19\">",
"      Goode PS, Burgio KL, Redden DT, et al. Population based study of incidence and predictors of urinary incontinence in black and white older adults. J Urol 2008; 179:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/20\">",
"      Burgio KL, Zyczynski H, Locher JL, et al. Urinary incontinence in the 12-month postpartum period. Obstet Gynecol 2003; 102:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/21\">",
"      Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Tr&oslash;ndelag. J Clin Epidemiol 2000; 53:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/22\">",
"      Lifford KL, Townsend MK, Curhan GC, et al. The epidemiology of urinary incontinence in older women: incidence, progression, and remission. J Am Geriatr Soc 2008; 56:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/23\">",
"      Anger JT, Saigal CS, Litwin MS, Urologic Diseases of America Project. The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. J Urol 2006; 175:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/24\">",
"      Benner JS, Becker R, Fanning K, et al. Bother related to bladder control and health care seeking behavior in adults in the United States. J Urol 2009; 181:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/25\">",
"      Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/26\">",
"      Stewart, W, Herzog, R, Wein, A, et al. The prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 2001; 20:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/27\">",
"      Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J Urol 2004; 11:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/28\">",
"      Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/29\">",
"      Stothers L, Thom D, Calhoun E. Urologic diseases in America project: urinary incontinence in males--demographics and economic burden. J Urol 2005; 173:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/30\">",
"      Thom DH, Nygaard IE, Calhoun EA. Urologic diseases in America project: urinary incontinence in women-national trends in hospitalizations, office visits, treatment and economic impact. J Urol 2005; 173:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/31\">",
"      Subak LL, Brubaker L, Chai TC, et al. High costs of urinary incontinence among women electing surgery to treat stress incontinence. Obstet Gynecol 2008; 111:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/32\">",
"      Subak LL, Brown JS, Kraus SR, et al. The \"costs\" of urinary incontinence for women. Obstet Gynecol 2006; 107:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/33\">",
"      Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/34\">",
"      Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/35\">",
"      Herzog AR, Diokno AC, Brown MB, et al. Urinary incontinence as a risk factor for mortality. J Am Geriatr Soc 1994; 42:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/36\">",
"      DuBeau CE, Levy B, Mangione CM, Resnick NM. The impact of urge urinary incontinence on quality of life: importance of patients' perspective and explanatory style. J Am Geriatr Soc 1998; 46:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/37\">",
"      Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc 2006; 54:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/38\">",
"      Landefeld CS, Bowers BJ, Feld AD, et al. National Institutes of Health state-of-the-science conference statement: prevention of fecal and urinary incontinence in adults. Ann Intern Med 2008; 148:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/39\">",
"      Subak LL, Richter HE, Hunskaar S. Obesity and urinary incontinence: epidemiology and clinical research update. J Urol 2009; 182:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/40\">",
"      Melville JL, Katon W, Delaney K, Newton K. Urinary incontinence in US women: a population-based study. Arch Intern Med 2005; 165:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/41\">",
"      Grodstein F, Fretts R, Lifford K, et al. Association of age, race, and obstetric history with urinary symptoms among women in the Nurses' Health Study. Am J Obstet Gynecol 2003; 189:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/42\">",
"      Brown JS, Sawaya G, Thom DH, Grady D. Hysterectomy and urinary incontinence: a systematic review. Lancet 2000; 356:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/43\">",
"      Ouslander JG. Management of overactive bladder. N Engl J Med 2004; 350:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/44\">",
"      Jackson SL, Scholes D, Boyko EJ, et al. Urinary incontinence and diabetes in postmenopausal women. Diabetes Care 2005; 28:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/45\">",
"      Jura YH, Townsend MK, Curhan GC, et al. Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J Urol 2011; 185:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/46\">",
"      Elia G, Bergman J, Dye TD. Familial incidence of urinary incontinence. Am J Obstet Gynecol 2002; 187:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/47\">",
"      Hannestad YS, Lie RT, Rortveit G, Hunskaar S. Familial risk of urinary incontinence in women: population based cross sectional study. BMJ 2004; 329:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/48\">",
"      Tinetti ME, Inouye SK, Gill TM, Doucette JT. Shared risk factors for falls, incontinence, and functional dependence. Unifying the approach to geriatric syndromes. JAMA 1995; 273:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/49\">",
"      Kuchel GA, Moscufo N, Guttmann CR, et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2009; 64:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/50\">",
"      Resnick, NM, Elbadawi, A, Yalla, SV. Age and the lower urinary tract: What is normal? Neurourol Urodynam 1995; 14:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/51\">",
"      Griffiths D, Tadic SD, Schaefer W, Resnick NM. Cerebral control of the bladder in normal and urge-incontinent women. Neuroimage 2007; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/52\">",
"      Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008; 9:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/53\">",
"      DeLancey JO. Structural aspects of the extrinsic continence mechanism. Obstet Gynecol 1988; 72:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/54\">",
"      Andersson KE. Bladder activation: afferent mechanisms. Urology 2002; 59:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/55\">",
"      Smith PP. Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn 2010; 29:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/56\">",
"      Taylor JA 3rd, Kuchel GA. Detrusor underactivity: Clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 2006; 54:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7192/abstract/57\">",
"      Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005; 293:935.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6875 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-8A73E14F39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7192=[""].join("\n");
var outline_f7_1_7192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Costs to society",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Quality of life impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS AND CONTRIBUTING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Normal micturition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Age-related changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6875\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6875|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/28/22976\" title=\"figure 1\">",
"      Physiology normal micturition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6875|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/18/21805\" title=\"table 1\">",
"      Comorbid conditions of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/11/3261\" title=\"table 2\">",
"      Meds that worsen UI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=related_link\">",
"      Nocturia: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=related_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=related_link\">",
"      Patient information: Treatments for urge incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=related_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=related_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41737?source=related_link\">",
"      Urinary incontinence in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_1_7193="Assessment of the pediatric patient for potential organ donation";
var content_f7_1_7193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of the pediatric patient for potential organ donation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7193/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7193/contributors\">",
"     Harish Vyas, DM, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7193/contributors\">",
"     Shaun Wilson, DCH, MRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7193/contributors\">",
"     Thomas A Nakagawa, MD, FAAP, FCCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7193/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/1/7193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/1/7193/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/1/7193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organ transplantation has become the treatment of choice for end-stage organ failure, transforming the outlook and quality of life for affected children. Organ transplantation procedures were first performed in adults in the 1950s and in children in the 1960s. Since then, advances in surgical techniques and immunosuppressive therapies have led to a marked increase in successful transplantation of organs and patient survival.",
"   </p>",
"   <p>",
"    Unfortunately, many individuals die while waiting for a needed organ because of the increasing gap between donors and recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/1\">",
"     1",
"    </a>",
"    ]. This is particularly true in children where size and weight constraints, technical challenges of transplantation in smaller children, and organ supply and organ demand issues continue to exist. Obstacles to recovery of organs from donors include: family or cultural resistance to organ donation, issues related to consent of families (including inappropriate timing and confusion regarding death of their child), medical staff perceptions and misunderstanding about organ donation, missed opportunities for donation (including medical examiner denials in child abuse cases), and inadequate donor management resulting in loss of viable organs for transplantation.",
"   </p>",
"   <p>",
"    There has been a substantial reduction in heart-beating organ donors, also referred to as standard criteria donors (SCD), in the last decade in the United Kingdom and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The decline in donors exists for several reasons. Morbidity and mortality in children has been reduced from improved antibiotic therapies, more effective immunizations, use and refinement of passenger safety restraint systems, helmets, and other safety measures. Additionally, care provided by specialists trained in pediatric intensive care has significantly improved chances for survival of children with life-threatening disease. Adverse publicity associated with reports of unauthorized or inappropriate use of organs may have also contributed to families and loved ones denying consent for donation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the increasing gap between organ availability and recipient need, it is necessary to maximize the recovery of organs from the existing donor pool. Therefore, all families facing end-of-life issues should be offered the opportunity of organ donation. Decisions about organ donation are influenced by individual factors as well as cultural beliefs. When approached in a sensitive manner, most families report that organ donation is a \"positive experience\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The assessment of the pediatric patient for potential organ donation is discussed in this chapter. The diagnosis of death by neurologic criteria and management of the potential organ donor are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link\">",
"     \"Diagnosis of brain death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24874?source=see_link\">",
"     \"Management of the potential pediatric organ donor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF NEUROLOGIC DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic death must be distinguished from persistent vegetative state (PVS). In PVS, the brainstem remains intact and functions to maintain respiratory effort and normal circulation, while the patient's cortical function has been significantly impaired or lost. In this state, the patient may or may not have an awareness of self or environment. These patients cannot be declared legally dead because their brainstem function remains intact.",
"   </p>",
"   <p>",
"    The fundamental definition of neurologic death is similar in most countries, although the procedures required to establish the diagnosis vary. Countries such as the United States and Canada require physical examination to determine death of the entire brain, including the brainstem. If examination criteria cannot be met, ancillary studies are required to determine death by neurologic criteria. This differs from the United Kingdom, where only testing of brainstem reflexes is required to determine death. Additionally, in the United States, required observation times depend on the age of the child. The diagnosis of neurologic death, including considerations related to the pediatric patient, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link\">",
"     \"Diagnosis of brain death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this review, we will use the term \"neurologic death\" to describe the condition meeting the legal and medical definitions for death based on the region of practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DONOR IDENTIFICATION AND SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients declared dead by neurologic criteria with intact cardiovascular function are known as \"heartbeating donors,\" and remain the most common source of organs for transplantation (",
"    <a class=\"graphic graphic_table graphicRef75152 \" href=\"UTD.htm?1/56/1931\">",
"     table 1",
"    </a>",
"    ). In the United States, the terms \"deceased donor\" or standard criteria donor (SCD) are commonly used. These patients are cared for in an intensive care unit, where vital functions are artificially maintained using assisted ventilation and, in some cases, inotropic support. They have suffered irreversible brain damage resulting in neurologic death and are unable to breathe on their own if removed from mechanical ventilatory support. Following identification of the patient as a potential donor and the diagnosis of neurologic death, it is important that aggressive intensive medical care is continued to ensure that donor organs remain viable for transplantation. Such care is thought to markedly enhance long term organ survival in the recipient and increase the chance of recovering suitable organs from potential donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24874?source=see_link\">",
"     \"Management of the potential pediatric organ donor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physicians caring for any potential organ donor should consider accessing transplant coordinators from the local Organ Procurement Organization (OPO) even before neurologic death has formally been declared. Most OPOs have personnel that can facilitate communication with the family and support them, independent of the decision to donate, during the time period of donation or withdrawal of ventilatory support. The discussion between the physician and the OPO can help determine whether the patient may be a suitable donor. Even if solid organs are not suitable for recovery, tissue donation, including eyes, skin, bone and heart valves may be considered.",
"   </p>",
"   <p>",
"    The ideal donor has an isolated head injury, with limited or no other organ system dysfunction or pre-existing comorbid diseases such as diabetes or hypertension. Patients with multi-system organ failure due to toxic drug ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/7\">",
"     7",
"    </a>",
"    ], meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/8\">",
"     8",
"    </a>",
"    ], sepsis and even primary brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], who may not be ideal candidates for donation initially, can be aggressively managed following declaration of neurologic death and potentially provide additional organs for transplantation. Although the majority of such patients are already in intensive care units, patients admitted to the emergency department may also be potential candidates for organ donation, and early notification of the OPO should be encouraged.",
"   </p>",
"   <p>",
"    The potential donor should meet all of the following criteria to be considered for organ recovery:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neurologic death",
"     </li>",
"     <li>",
"      Treatment of any serious infection",
"     </li>",
"     <li>",
"      Free of malignancy with the exception of low-grade skin or brain tumors",
"     </li>",
"     <li>",
"      Free of systemic disease (eg, systemic lupus or end-stage renal disease)",
"     </li>",
"     <li>",
"      Hemodynamically stable (even with inotropic and pressor use)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS TO DONATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a progressive expansion in the types of donors and organs recovered for transplantation over the last two decades. It is imperative to discuss each potential donor with the Organ Procurement Organization (OPO). No assumptions about donor suitability should be made until discussions with the OPO have occurred. Decisions regarding organ recovery are made by the OPO and their medical director, not by the medical team managing the potential donor. Additionally, early involvement of the OPO can spare the family the discouraging news that their child cannot be a donor because of an underlying disease process, unsuitable organs, or lack of recipients to receive a transplanted organ.",
"   </p>",
"   <p>",
"    Human immunodeficiency virus (HIV) and active cytomegalovirus (CMV) infections remain absolute contraindications. Other disease processes, such as infectious illnesses, uncontrolled malignancies, or risk factors for these diseases also are strong contraindications to organ donation (",
"    <a class=\"graphic graphic_table graphicRef54994 \" href=\"UTD.htm?12/61/13275\">",
"     table 2",
"    </a>",
"    ). Risk factors for HIV infection, such as intravenous drug use, may exclude a patient from becoming a donor; however, this is not commonly encountered in children.",
"   </p>",
"   <p>",
"    Novel strategies are emerging to help increase the supply of organs needed for transplantation into critically ill patients. As an example, donation from hepatitis B and C positive patients may be considered for recipients who are already infected with the same virus, or in exceptional circumstances, for recipients at risk of imminent death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/11\">",
"     11",
"    </a>",
"    ]. Isolated liver disease or end stage heart disease in the donor precludes transplantation of these damaged organs. However, disease affecting one organ should not prevent recovery of other organs, unless the disease process causes or would predispose to widespread organ failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FAMILY COMMUNICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the onset and declaration of neurologic death, the support and care offered to families should be intensified rather than withdrawn. Everyone involved in the intensive care unit plays an integral role in managing a potential donor and their family.",
"   </p>",
"   <p>",
"    In the United States, hospitals participating in government-funded programs are mandated to refer all potential organ donors to their local OPO, and to inform families of their option to donate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Each unit should have a policy that sets out a strategy for communication and support with families of potential donors. Such policies are ideally developed by a multi-disciplinary team, consisting of medical staff, nursing personnel, psychologists, child life specialists, chaplain services, OPO personnel, and family service coordinators [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Communication with the family should be conducted in a caring, compassionate, and sympathetic manner. The attending physician and the critical care nurses who have been involved in the patient's ante-mortem management should meet directly with the family in a quiet environment that is free of distractions. Utilizing chaplain and social services can also provide additional support for the family.",
"   </p>",
"   <p>",
"    The physician's main role is to communicate that the child has died and to ensure that the family understands the finality of neurologic death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. A common reason for parents to deny consent for donation is lack of acceptance of their child's death. Ensuring that the parents understand that their child is dying or has died is an imperative message that must be consistently conveyed by the healthcare team. Team members must collaborate with physicians in using consistent, uncomplicated terminology. The medical and legal definition of neurologic death is complex and often confusing even for physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], and families do not tend to make a distinction between cardiac and neurologic death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/21\">",
"     21",
"    </a>",
"    ]. Therefore, it may be helpful to use general terms such as \"death\" when possible, rather than \"brain death\" or \"neurologic death\".",
"   </p>",
"   <p>",
"    Explaining to the family that their child's life has ended and allowing them time to accept this reality should usually occur prior to the discussion of organ donation. The discussion of organ donation should not be raised during the same interview, unless the issue is raised by the family. The separation of the two discussions, described as \"decoupling,\" has been shown to increase the chance of a positive decision by the family regarding donation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/13,14,16\">",
"     13,14,16",
"    </a>",
"    ]. Alternatively, some parents respond positively if they are exposed to organ donation information prior to the child's death, and have time to discuss donation among themselves before the death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/5\">",
"     5",
"    </a>",
"    ]. Early and continued involvement of the OPO is essential in the discussions of organ donation with families [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/14\">",
"     14",
"    </a>",
"    ]. This collaboration enhances the chance of parents consenting to donation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DONOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient has been declared dead by neurologic criteria and the family has consented, laboratory evaluation of the potential donor continues with both general and organ specific testing. These screening tests differ from center to center. The goals are to determine tissue type and basic donor immunology, assess organ function, and identify any underlying infection or contraindication to donation (",
"    <a class=\"graphic graphic_table graphicRef54890 \" href=\"UTD.htm?23/48/24331\">",
"     table 3",
"    </a>",
"    ). Laboratory testing generally includes ABO blood type, complete blood count (CBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), Gammaglutamyl transpeptidase (GGT), prothrombin time (PT), partial thromboplastin time (PTT), hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc), hepatitis C antibody (anti-HCV), human immunodeficiency virus antibody (anti-HIV), serologic tests for syphilis (VDRL or RPR), and cytomegalovirus antibody (anti-CMV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Specific organ considerations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;General considerations for donor selection for liver transplantation, including the components of the evaluation by the organ procurement organization, donor exclusion criteria and ABO matching are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/9/21656?source=see_link\">",
"     \"Donor selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum albumin, PT, and PTT provide an index of liver synthetic function, but may be affected by administration of blood products or disseminated intravascular coagulation. Additionally, anoxia or the cause of donor death may compromise liver function. If the AST, ALT, and GGT normalize after resuscitation, the liver may be suitable for transplantation. Organs from donors with serologic evidence of viral hepatitis may also be appropriate for transplantation under special conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/9/21656?source=see_link\">",
"     \"Donor selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organ allocation &ndash; The most common indication for hepatic transplant in the pediatric population is extrahepatic biliary atresia, followed by metabolic disorders, and acute liver failure. These organ recipients represent a wide range of age and size, including infants. Development of the Pediatric End Stage Liver Disease (PELD) scoring system has changed the strategy for distribution of livers to pediatric recipients. Livers are offered first to patients with the highest risk of mortality based on their PELD score, modified by other considerations, including blood type similarity and region, and (to a lesser extent) waiting time [",
"      <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/22\">",
"       22",
"      </a>",
"      ]. The PELD score is calculated by the United Network for Organ Sharing (UNOS). The clinical team can also estimate the PELD score using a mathematical calculation (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/40/9860?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). For recipients over 12 years of age, the Model of End-Stage Liver Disease (MELD) score is used. The MELD score is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"       \"Model for End-stage Liver Disease (MELD)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Size considerations &ndash; Because of size considerations, livers from pediatric donors are offered first to pediatric recipients. Livers can be split for multiple donation and segment transplantation into smaller patients. Because this approach confers additional technical challenges, transplantation of an intact liver from a pediatric donor into a similar sized recipient may be preferred [",
"      <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/23\">",
"       23",
"      </a>",
"      ]. However, considerations such as the severity of illness and size of the recipient may require consideration of split liver transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Living donors and split livers from deceased donors represent important sources of livers for pediatric transplant recipients. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=see_link\">",
"     \"Living donor liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/9/21656?source=see_link&amp;anchor=H21#H21\">",
"     \"Donor selection for liver transplantation\", section on 'Split-liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrinsic renal disease and parenchymal trauma are exclusion criteria for donation. Risk factors for graft failure include technical issues during implantation, degree of immune sensitivity in the recipient, and pre-recovery tissue injury (eg, ischemia and hypoxia); these apply to donors of all ages. The benefits of living donor transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kidneys from donors younger than three years are sometimes discarded because there is an increased risk of graft thrombosis, however, the en bloc technique, in which both kidneys are recovered together and transplanted with the vascular pedicle, has been used with good success rates in small adult recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/24\">",
"     24",
"    </a>",
"    ]. Unfortunately, the high risk of vascular complications limits the use of this procedure in children. Renal mass must be adequate for the size of the recipient, and is a predictor of graft failure, so kidneys from small pediatric donors should be allocated first to recipients of similar weight [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/25\">",
"     25",
"    </a>",
"    ]. Each case must be discussed with the transplant surgeon to determine if the kidneys will meet the need of the potential recipient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk factors for graft failure in kidney transplantation\", section on 'Inadequate renal mass'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and decision about whether to recover a kidney from a potential donor will be directed by the Organ Procurement Organization (OPO) and transplant surgeons, based upon organ function, disease process, and underlying circumstances that resulted in the death of the donor. Assessment of the potential donor in the intensive care unit frequently includes the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal function &ndash; Ideal donors generally have serum creatinine levels of less than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/liter).",
"      </span>",
"      Elevated creatinine levels &gt;1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (170",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      can be a predictor of poor graft function, and require further evaluation to determine renal function. However, kidneys with impaired renal function from acute tubular necrosis have been transplanted successfully with recovery of renal function following transplantation. The recipient may require temporary support with dialysis following transplantation until renal function recovers. A urinalysis is also important to assess for casts and protein excretion and presence of infection. A urine culture is also sent prior to organ recovery.",
"     </li>",
"     <li>",
"      Kidney biopsies are currently required by UNOS (United Network of Organ Sharing) in older patients to further evaluate suitability of the organ for transplantation. The results are also used to classify the donor as standard or expanded criteria (ECD) for allocation to potential transplant centers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The kidney allocation policy used in the United States, including expanded criteria donors (ECD) and special considerations given to pediatric organ recipients, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor selection for potential cardiac recovery is particularly stringent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. There should be no history of pre-existing coronary or valvular disease. Inotropic support should be minimized, and adjusted to maintain a normal blood pressure for age. Increased need for inotropic support with concomitant lactic acidosis may indicate poor cardiac performance and requires careful evaluation for the causes of dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24874?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of the potential pediatric organ donor\", section on 'Inotropes and vasopressors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to recover and transplant a heart from a potential donor will be made by the OPO and transplant surgeon based upon organ function, size, disease process, and underlying circumstances that resulted in the death of the donor, just like any other potential organ for transplantation. Organ assessment in intensive care includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest radiograph",
"     </li>",
"     <li>",
"      Echocardiogram",
"     </li>",
"     <li>",
"      12 lead EKG",
"     </li>",
"     <li>",
"      Cardiac enzymes (troponin and CK-MB)",
"     </li>",
"     <li>",
"      Cardiac angiography (in selected cases)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The echocardiogram should be performed after stabilization of the donor. Echocardiograms performed immediately following neurologic death will likely have evidence of ischemic changes related to the catecholamine storm and hypertension that ensues prior to brainstem herniation. In the older child, a pulmonary artery catheter may be requested to further define cardiac function.",
"   </p>",
"   <p>",
"    Cardiac size may limit transplantation for the potential recipient to accept the donated organ. While it might be reasonable to transplant a smaller heart into a bigger person, the converse is not true. Specific measurements will be conducted to determine if the heart is the appropriate size for the recipient.",
"   </p>",
"   <p>",
"    The surgeon, with background knowledge of the hemodynamic parameters, performs the final assessment of ventricular function visually during the organ recovery procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor lungs are the organ most likely to be compromised for transplantation. Management of the potential donor requires particular care to monitor and protect the lungs from excessive volume administration, which can leading to pulmonary edema and high pressures that can ultimately affect suitability of the lung for transplantation. Pressure ventilation is preferred by most thoracic transplant surgeons with early and aggressive bronchoscopy for bacterial culture and pulmonary toilet. Criteria defining the ideal characteristics of a lung donor include are an age less than 60 years, a normal chest radiograph, good gas exchange, and no history of either primary pulmonary disease, aspiration, or cardiopulmonary surgery. Relative and absolute exclusion criteria are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12425?source=see_link\">",
"     \"Lung transplantation: Deceased donor evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Organ assessment in the intensive care unit requires:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygen challenge test and serial arterial blood gas analysis &ndash; To determine whether the patient's lungs are suitable for organ donation, an oxygen challenge is performed. The potential donor is preoxygenated with an FiO2 of 1.0, and PaO2 is measured. If the PaO2 is &gt;300 mmHg, the lungs are considered suitable for donation in many centers. Values lower than this threshold suggest lung injury, infection,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atelectasis. Because low values may be caused by atelectasis, alveolar recruitment may be achieved by strategies to improve oxygenation. Serial analysis of arterial blood gas between oxygen challenge tests provides further information about respiratory function and response to interventions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24874?source=see_link&amp;anchor=H16#H16\">",
"       \"Management of the potential pediatric organ donor\", section on 'Respiratory'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest radiographs &ndash; These should be performed every 4 to 12 hours (or as recommended by the OPO protocol) to assess for development of infiltrates",
"     </li>",
"     <li>",
"      Bronchoscopy &ndash; Bronchoscopy is a valuable tool for the initial assessment of the potential lung donor, as it may identify potential pathogens to guide antibiotic therapy; the procedure also provides the possibility of therapeutic bronchial toilet. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24874?source=see_link&amp;anchor=H16#H16\">",
"       \"Management of the potential pediatric organ donor\", section on 'Respiratory'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lung transplantation typically requires size matching of the donor and recipient. This is usually based on donor and recipient height, although some centers also use estimates of lung volume made from chest radiographs. Lobar transplantation or reduction of the lung size by surgical stapling has been reported for pediatric recipients when donor lung size is excessive [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12425?source=see_link&amp;anchor=H5#H5\">",
"     \"Lung transplantation: Deceased donor evaluation and management\", section on 'Size matching'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ORGAN PROCUREMENT STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All inpatient hospital deaths, including deaths in the emergency department, should be audited. Audits restricted to the ICU or confirmed brain dead patients will underestimate the potential donor pool [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/32\">",
"     32",
"    </a>",
"    ]. In the United States, deaths are reported to the Organ Procurement Organization (OPO) and reviewed as required by federal guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Donation after circulatory determination of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the gap between the number of patients waiting for a transplant and the number of available organs continues to grow, alternative sources are increasingly utilized to expand the donor pool. Donation after cardiac death is an increasingly important source of organs for transplantation. This type of donor does not meet criteria for neurologic death (and is not expected to progress to that state), but has no hope of any sort of meaningful neurologic recovery. In these situations, the family will often choose to withdraw life sustaining treatment. Once this decision has been made by the family, the OPO and medical personnel can approach the family and offer the possibility of donating organs after cardiocirculatory death has been declared. The donation decision does not alter end-of-life care for the patient.",
"   </p>",
"   <p>",
"    After ventilatory support is discontinued and cardiocirculatory death is determined, organs are recovered for transplantation only if the patient has ceased cardiocirculatory function within an acceptable window of warm ischemia time (usually 30 to 60 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/33\">",
"     33",
"    </a>",
"    ]. This type of donation is referred to as donation after circulatory determination of death (DCDD), non heart-beating donation (NHBD), or donation after cardiac death (DCD).",
"   </p>",
"   <p>",
"    In a 1997 review, the Institute of Medicine in the United States concluded that transplantation or organs from DCDD donors is an ethically acceptable and medically useful method to increase the available supply of organs for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/34\">",
"     34",
"    </a>",
"    ]. The Ethics Committee of the Society of Critical Care Medicine and the National Conference on Organ Donation after Cardiac Death, and the American Academy of Pediatrics also support DCDD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/14,35,36\">",
"     14,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While most donated organs still come from standard criteria donors (SCD), or heartbeating donors declared dead by neurologic criteria, the use of organs from this select donor pool could substantially increase the supply of organs available for pediatric recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Although few organs are recovered from DCDD donors at any one institution, the total number from all children's hospitals could substantially increase the number of organs available for transplantation. Most children's hospitals in the United States have or are developing policies regarding DCDD, but there is considerable variation among these policies regarding procedures and personnel for declaring death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, use of organs from DCDD donors has more than doubled since 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/37\">",
"     37",
"    </a>",
"    ] and continues to increase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/42\">",
"     42",
"    </a>",
"    ]. Organs recovered for transplantation from DCDD donors have been primarily kidneys and livers. Rates of graft survival for organs from DCDD donors are similar to those for organs recovered from heartbeating donors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. One report noted that 74 percent of kidneys and 90 percent of livers recovered from DCDD were transplanted with good success [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/48\">",
"     48",
"    </a>",
"    ]. DCDD transplantation from adult donors is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18566?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of the potential deceased donor\", section on 'Donation after death determined using cardiac criteria (non-heart-beating donor)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data is slowly emerging suggesting positive outcomes for children who have received DCDD organs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Lung transplants from DCDD donors have also occurred in several institutions in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A report of three neonatal heart transplants from DCDD donors performed under a research protocol has been published; however, this practice is not commonly accepted or applied in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/54\">",
"     54",
"    </a>",
"    ]. Neonatal donation is another promising area for recovery of organs to potentially increase organs available for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MODELS FOR INCREASING ORGAN DONATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;National laws differ as to whether or not consent is \"presumed\" (assuming that an individual wants to donate their organs after death). In the United States and the United Kingdom, consent is not presumed, although a large proportion of the population support organ donation. By contrast, Spain operates under presumed consent, in which consent is presumed unless individuals have left evidence of their intentions to the contrary.",
"   </p>",
"   <p>",
"    The assumption of presumed consent enhances the effective consent rate and the \"conversion rate\" (number of eligible deceased donors for which consent is obtained) (",
"    <a class=\"graphic graphic_table graphicRef80579 \" href=\"UTD.htm?10/20/10573\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/57\">",
"     57",
"    </a>",
"    ]. There may, however, be a downside to presumed consenting, because it may lead to lower rates of living kidney transplantation. This needs to be taken into account before presumed consent is adopted as a national strategy (",
"    <a class=\"graphic graphic_figure graphicRef83543 \" href=\"UTD.htm?30/46/31470\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/58\">",
"     58",
"    </a>",
"    ]. Other factors, such as the availability of life-sustaining technology and care provided in intensive care units by trained specialists also contribute to overall donor rates in a population and successful organ recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Organ Donation Breakthrough Collaborative was initiated in 2003 to increase rates of organ donation in the United States. Through these efforts, the number of deceased organ donors has increased an average of 8 percent per year since 2003, with a 40 percent increase in deceased donors since 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/59\">",
"     59",
"    </a>",
"    ]. This growth is most impressive when compared to the relatively static number of donors for the previous 10 years. A large proportion of the increase in donors is due to the use of DCDD donors (non heart-beating donors), and extended criteria donors (ECD), in whom age or other concomitant disease may predict suboptimal graft function and survival. Other important elements of the strategy include placing hospital-based organ procurement coordinators within active donor hospitals, encouragement of early involvement of the Organ Procurement Organization (OPO) in the donation process, and collaboration with intensive care specialists. For pediatric donation, collaboration between OPO coordinators and pediatric intensivists is particularly crucial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the United States operates under a \"required\" rather than \"presumed\" consent system, organized internet-based records of intent have provided an important tool to assist in increasing donation rates. In virtually every state, donor registries have been established, which allow healthy individuals express their intent to donate their organs after death. Through these statewide registries and the databases of the Department of Motor Vehicles, approximately 27 percent of individuals over 16 years old have enrolled in a donor registry [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Spain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spain's donor rate is unusually high and has increased from 14.3 donors per million in 1989 to 33.7 per million in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/60\">",
"     60",
"    </a>",
"    ], as compared to rates between 12 and 22 per million in other European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/1/7193/abstract/61\">",
"     61",
"    </a>",
"    ]. This donor rate is attributable to a policy of presumed consent, and to highly organized systems for donor identification and conversion.",
"   </p>",
"   <p>",
"    The Spanish government established an integrated system for identification and management of potential donors. This system was organized at local, regional, and national levels, with central government funding. The system includes a centralized transplant registry and waiting list management, and hospital-based transplant coordinators who are responsible for organ procurement and communication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organ transplantation has become the treatment of choice for end-stage organ failure in carefully selected individuals, but many candidates die while waiting for a needed organ because of the increasing gap between the numbers of donors and recipients. This is particularly true for children, for whom size and weight constraints place additional burden on finding suitable organs for transplantation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most organs used for transplantation come from heartbeating, or standard criteria donors (SCD), who have been declared dead by neurologic criteria. However, more organs are being recovered from donors who have died after meeting circulatory respiratory criteria or donation after circulatory determination of death (DCDD). Neonatal donation is another area of growth that may provide more needed organs for children. Early identification and management of the potential donor increases the likelihood of successful recovery of organs for transplantation. The process ideally requires a specialized team led by pediatric intensivists, in close consultation with the local Organ Procurement Organization (OPO) and transplant physicians and surgeons. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Donor identification and selection'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Families of all potential donors should be given the opportunity of organ donation. Donation is a decision made by the family, not by the medical team. The care team should provide support for the grieving family and communicate clear messages about the finality of neurologic death, using sensitivity and simple terms. The opportunity of organ donation should be offered in a separate interview, unless parent-initiated conversations regarding donation occurs prior to declaration of death. Early involvement of the OPO and transplant coordinators can facilitate effective communication and family support. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Family communication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation of the potential donor is performed to determine tissue type and basic donor serology, assess organ function, and identify any underlying infection or contraindications to donation (",
"      <a class=\"graphic graphic_table graphicRef54890 \" href=\"UTD.htm?23/48/24331\">",
"       table 3",
"      </a>",
"      ). No assumptions about donor suitability should be made until discussions with the OPO have occurred. Pediatric donors are subject to additional organ-specific size considerations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Donor screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Data. The Organ Procurement and Transplantation Network. www.optn.org/data (Accessed on October 06, 2008).",
"    </li>",
"    <li>",
"     Royal College of Surgeons of England. Report of the working party to review organ transplantation, 1999. Available at: file://www.rcseng.ac.uk/publications/docs/review_organ_report.html (Accessed on October 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/3\">",
"      English V, Sommerville A. Presumed consent for transplantation: a dead issue after Alder Hey? J Med Ethics 2003; 29:147.",
"     </a>",
"    </li>",
"    <li>",
"     National Kidney Foundation. www.kidney.org/general/news/newsitem.cfm?id=29 (Accessed on September 10, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/5\">",
"      Rodrigue JR, Cornell DL, Howard RJ. Pediatric organ donation: what factors most influence parents' donation decisions? Pediatr Crit Care Med 2008; 9:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/6\">",
"      Morris JA Jr, Wilcox TR, Frist WH. Pediatric organ donation: the paradox of organ shortage despite the remarkable willingness of families to donate. Pediatrics 1992; 89:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/7\">",
"      Powner DJ, Delgado E. Using pressure-limited mechanical ventilation in caring for organ donors. Prog Transplant 2001; 11:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/8\">",
"      Satoi S, Bramhall SR, Solomon M, et al. The use of liver grafts from donors with bacterial meningitis. Transplantation 2001; 72:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/9\">",
"      Punnett AS, McCarthy LJ, Dirks PB, et al. Patients with primary brain tumors as organ donors: case report and review of the literature. Pediatr Blood Cancer 2004; 43:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/10\">",
"      Buell JF, Trofe J, Sethuraman G, et al. Donors with central nervous system malignancies: are they truly safe? Transplantation 2003; 76:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/11\">",
"      Marelli D, Bresson J, Laks H, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant 2002; 2:443.",
"     </a>",
"    </li>",
"    <li>",
"     Omnibus Reconciliation Act. Pub L No. 99&ndash;509 (1986).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/13\">",
"      Pediatric Organ Donation and Transplantation: policy statement: organizational principles to guide and define the child health care system and/or improve the health of all children: Committee on Hospital Care and Section on Surgery. American Academy of Pediatrics. Pediatrics 2002; 109:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/14\">",
"      Committee on Hospital Care, Section on Surgery, and Section on Critical Care. Policy statement--pediatric organ donation and transplantation. Pediatrics 2010; 125:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/15\">",
"      Valdes M, Johnson G, Cutler JA. Organ donation after neurologically unsurvivable injury: a case study with ethical implications for physicians. Proc (Bayl Univ Med Cent) 2002; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/16\">",
"      Garrison RN, Bentley FR, Raque GH, et al. There is an answer to the shortage of organ donors. Surg Gynecol Obstet 1991; 173:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/17\">",
"      Gortmaker SL, Beasley CL, Sheehy E, et al. Improving the request process to increase family consent for organ donation. J Transpl Coord 1998; 8:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/18\">",
"      Mejia RE, Pollack MM. Variability in brain death determination practices in children. JAMA 1995; 274:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/19\">",
"      Rachmani R. Physicians' and nurses' attitudes and knowledge toward brain death. Transplant Proc 1999; 31:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/20\">",
"      Chang MY, McBride LA, Ferguson MA. Variability in brain death declaration practices in pediatric head trauma patients. Pediatr Neurosurg 2003; 39:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/21\">",
"      Truog RD, Christ G, Browning DM, Meyer EC. Sudden traumatic death in children: \"we did everything, but your child didn't survive\". JAMA 2006; 295:2646.",
"     </a>",
"    </li>",
"    <li>",
"     Organ Distribution: Allocation of Livers www.unos.org/PoliciesandBylaws2/policies/pdfs/policy_8.pdf (Accessed on September 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/23\">",
"      Broelsch CE, Emond JC, Whitington PF, et al. Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants. Ann Surg 1990; 212:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/24\">",
"      Keitel E, Fasolo LR, D'Avila AR, et al. Results of en bloc renal transplants of pediatric deceased donors into adult recipients. Transplant Proc 2007; 39:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/25\">",
"      Bar-Dayan A, Bar-Nathan N, Shaharabani E, et al. Kidney transplantation from pediatric donors: size-match-based allocation. Pediatr Transplant 2008; 12:469.",
"     </a>",
"    </li>",
"    <li>",
"     Nakagawa TA, Mou SS, American Transplant Coordinators Organization (NATCO). Management of the pediatric organ donor. In: The Clinician's Guide to Donation and Transplantation, Applied Measurement Professionals Inc, Lenexa, KS 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/27\">",
"      Lutz-Dettinger N, de Jaeger A, Kerremans I. Care of the potential pediatric organ donor. Pediatr Clin North Am 2001; 48:715.",
"     </a>",
"    </li>",
"    <li>",
"     Nakagawa TA. Updated pediatric donor management and dosing guidelines. North American Transplant Coordinators Organization (NATCO). Available at: www.natco1.org/prof_development/index.htm#guidelines (Accessed on September 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/29\">",
"      Aigner C, Mazhar S, Jaksch P, et al. Lobar transplantation, split lung transplantation and peripheral segmental resection--reliable procedures for downsizing donor lungs. Eur J Cardiothorac Surg 2004; 25:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/30\">",
"      Santos F, Lama R, Alvarez A, et al. Pulmonary tailoring and lobar transplantation to overcome size disparities in lung transplantation. Transplant Proc 2005; 37:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/31\">",
"      Keating DT, Westall GP, Marasco SF, et al. Paediatric lobar lung transplantation: addressing the paucity of donor organs. Med J Aust 2008; 189:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/32\">",
"      Opdam HI, Silvester W. Identifying the potential organ donor: an audit of hospital deaths. Intensive Care Med 2004; 30:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/33\">",
"      Zawistowski CA, DeVita MA. Non-heartbeating organ donation: a review. J Intensive Care Med 2003; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Non-Heart-Beating Organ Transplantation: Medical and Ethical Issues in Procurement, National Academy Press, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/35\">",
"      Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Recommendations for nonheartbeating organ donation. A position paper by the Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 2001; 29:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/36\">",
"      Bernat JL, D'Alessandro AM, Port FK, et al. Report of a National Conference on Donation after cardiac death. Am J Transplant 2006; 6:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/37\">",
"      Durall AL, Laussen PC, Randolph AG. Potential for donation after cardiac death in a children's hospital. Pediatrics 2007; 119:e219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/38\">",
"      Koogler T, Costarino AT Jr. The potential benefits of the pediatric nonheartbeating organ donor. Pediatrics 1998; 101:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/39\">",
"      Pleacher KM, Roach ES, Van der Werf W, et al. Impact of a pediatric donation after cardiac death program. Pediatr Crit Care Med 2009; 10:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/40\">",
"      Fraser J, Thomas I, Fish R, et al. The potential for non-heart beating organ donation within a paediatric intensive care unit. Arch Dis Child 2011; 96:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/41\">",
"      Antommaria AH, Trotochaud K, Kinlaw K, et al. Policies on donation after cardiac death at children's hospitals: a mixed-methods analysis of variation. JAMA 2009; 301:1902.",
"     </a>",
"    </li>",
"    <li>",
"     Data from United Network for Organ Sharing, Pediatric transplantation committee www.unos.org (Accessed on October 17, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/43\">",
"      Weber M, Dindo D, Demartines N, et al. Kidney transplantation from donors without a heartbeat. N Engl J Med 2002; 347:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/44\">",
"      D'Alessandro AM, Fernandez LA, Chin LT, et al. Donation after cardiac death: the University of Wisconsin experience. Ann Transplant 2004; 9:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/45\">",
"      D'Alessandro AM, Odorico JS, Knechtle SJ, et al. Simultaneous pancreas-kidney (SPK) transplantation from controlled non-heart-beating donors (NHBDs). Cell Transplant 2000; 9:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/46\">",
"      Cooper JT, Chin LT, Krieger NR, et al. Donation after cardiac death: the university of wisconsin experience with renal transplantation. Am J Transplant 2004; 4:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/47\">",
"      Manzarbeitia CY, Ortiz JA, Jeon H, et al. Long-term outcome of controlled, non-heart-beating donor liver transplantation. Transplantation 2004; 78:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/48\">",
"      Reiner M, Cornell D, Howard RJ. Development of a successful non-heart-beating organ donation program. Prog Transplant 2003; 13:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/49\">",
"      Abt P, Kashyap R, Orloff M, et al. Pediatric liver and kidney transplantation with allografts from DCD donors: A review of UNOS data. Transplantation 2006; 82:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/50\">",
"      de Vries EE, Snoeijs MG, van Heurn E. Kidney donation from children after cardiac death. Crit Care Med 2010; 38:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/51\">",
"      Gozzini S, Perera MT, Mayer DA, et al. Liver transplantation in children using non-heart-beating donors (NHBD). Pediatr Transplant 2010; 14:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/52\">",
"      Snell GI, Levvey BJ, Oto T, et al. Early lung transplantation success utilizing controlled donation after cardiac death donors. Am J Transplant 2008; 8:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/53\">",
"      Oto T. Lung transplantation from donation after cardiac death (non-heart-beating) donors. Gen Thorac Cardiovasc Surg 2008; 56:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/54\">",
"      Boucek MM, Mashburn C, Dunn SM, et al. Pediatric heart transplantation after declaration of cardiocirculatory death. N Engl J Med 2008; 359:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/55\">",
"      Labrecque M, Parad R, Gupta M, Hansen A. Donation after cardiac death: the potential contribution of an infant organ donor population. J Pediatr 2011; 158:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/56\">",
"      Mathur M, Castleberry D, Job L. Identifying potential heart donors among newborns undergoing circulatory determination of death. J Heart Lung Transplant 2011; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/57\">",
"      Johnson EJ, Goldstein D. Medicine. Do defaults save lives? Science 2003; 302:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/58\">",
"      Horvat LD, Cuerden MS, Kim SJ, et al. Informing the debate: rates of kidney transplantation in nations with presumed consent. Ann Intern Med 2010; 153:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/59\">",
"      Punch JD, Hayes DH, LaPorte FB, et al. Organ donation and utilization in the United States, 1996-2005. Am J Transplant 2007; 7:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/60\">",
"      Matesanz R. Factors that influence the development of an organ donation program. Transplant Proc 2004; 36:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/1/7193/abstract/61\">",
"      Barber K, Falvey S, Hamilton C, et al. Potential for organ donation in the United Kingdom: audit of intensive care records. BMJ 2006; 332:1124.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1663 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7193=[""].join("\n");
var outline_f7_1_7193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF NEUROLOGIC DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DONOR IDENTIFICATION AND SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS TO DONATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FAMILY COMMUNICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DONOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Specific organ considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Kidneys",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Heart",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ORGAN PROCUREMENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Donation after circulatory determination of death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MODELS FOR INCREASING ORGAN DONATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Spain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/1663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/1663|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/46/31470\" title=\"figure 1\">",
"      Annual rates of renal transplant in selected countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/1663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/56/1931\" title=\"table 1\">",
"      Causes brain death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/61/13275\" title=\"table 2\">",
"      Exclusions organ donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/48/24331\" title=\"table 3\">",
"      Labs organ donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/20/10573\" title=\"table 4\">",
"      Organ donation rates by country",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/40/9860?source=related_link\" title=\"calculator 1\">",
"      Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=related_link\">",
"      Diagnosis of brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/9/21656?source=related_link\">",
"      Donor selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=related_link\">",
"      Living donor liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12425?source=related_link\">",
"      Lung transplantation: Deceased donor evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18566?source=related_link\">",
"      Management of the potential deceased donor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24874?source=related_link\">",
"      Management of the potential pediatric organ donor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=related_link\">",
"      Organ sharing in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_1_7194="Temporomandibular disorders in adults";
var content_f7_1_7194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Temporomandibular disorders in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./temporomandibular-disorders-in-adults/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./temporomandibular-disorders-in-adults/contributors\">",
"     Steven J Scrivani, DMD, DMedSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./temporomandibular-disorders-in-adults/contributors\">",
"     Noshir R Mehta, DMD, MDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./temporomandibular-disorders-in-adults/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./temporomandibular-disorders-in-adults/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./temporomandibular-disorders-in-adults/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./temporomandibular-disorders-in-adults/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"./temporomandibular-disorders-in-adults/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26338276\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporomandibular disorders (TMD) are common, but they are diagnostically challenging due to the complex anatomy and innervation of the head, face, and neck. TMD can be acute or chronic and defy easy classification. TMD is sometimes classified as a subtype of a secondary headache disorder [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/1\">",
"     1",
"    </a>",
"    ]. The common goals of managing temporomandibular disorders are to alleviate pain and improve jaw function.",
"   </p>",
"   <p>",
"    TMD is associated with substantial morbidity and affects individual work productivity and quality of life. In the United States, it is estimated that for every 100 million working adults, TMD contributes to 17.8 million lost work days annually [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of temporomandibular disorders. The evaluation of temporomandibular joint dislocation is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26340?source=see_link\">",
"     \"Reduction of temporomandibular joint (TMJ) dislocation\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1713551742\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of and risk factors for temporomandibular disorders (TMD) have been assessed in different study populations. In one survey of adults in the United Kingdom, the prevalence of orofacial pain was 26 percent, with 6 percent reporting pain in the temporomandibular joint (TMJ) and 6 percent reporting preauricular pain [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/3\">",
"     3",
"    </a>",
"    ]. Observational studies in patients with TMD have illustrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of TMD is about 1.5 times higher in women than men [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The greatest risk of onset of TMD is between the ages of 18 and 44 [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Non-Hispanic Caucasians have a higher risk for TMD [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/6\">",
"       6",
"      </a>",
"      ]. There does not seem to be an association with socioeconomic group.",
"     </li>",
"     <li>",
"      There is an association between chronic TMD and mood disorders and other psychiatric comorbidities [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/7-13\">",
"       7-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Individuals with rheumatoid arthritis (RA) are more likely to develop temporomandibular pain at some point [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/14\">",
"       14",
"      </a>",
"      ]. The prevalence of TMD in patients with RA ranges from 53 to 94 percent [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/15\">",
"       15",
"      </a>",
"      ]. In one observational study, individuals with more severe RA (erythrocyte sedimentation rate &ge;32.08",
"      <span class=\"nowrap\">",
"       mm/hour)",
"      </span>",
"      were at increased risk for TMD.",
"     </li>",
"     <li>",
"      TMD is weakly associated with teeth grinding (bruxism) [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/16\">",
"       16",
"      </a>",
"      ]. A systematic review showed a slight association between bruxism and TMD symptoms.",
"     </li>",
"     <li>",
"      Although not formally studied, gum chewing, pencil biting, pipe smoking, and other repetitive jaw motions and positions (eg, violinists, singers, and woodwind players), are thought to be associated with TMD pain [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1713551750\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a long time, the cause of temporomandibular disorders (TMD) was attributed to changes in dental occlusion (the alignment of the upper and lower teeth) that affected maxillomandibular position and function. Although there is a structural component to TMD, biologic, behavioral, environmental, and cognitive factors all play a role in the development of symptoms [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1713552171\">",
"    <span class=\"h2\">",
"     Joint trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma to temporomandibular joint (TMJ) ligaments, articular cartilage, disc, and bone produces oxidative stress and generates free radicals in the intraarticular space. Subsequent synovial fluid inflammation produces cytokines that cause degenerative TMJ disease [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Joint trauma can result from whiplash injuries, bruxism, or external injuries to the jaw [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/24\">",
"     24",
"    </a>",
"    ]. TMJ disc displacements can also cause TMD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26340?source=see_link\">",
"     \"Reduction of temporomandibular joint (TMJ) dislocation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1713552178\">",
"    <span class=\"h2\">",
"     Pain threshold",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also a subjective component to the perception of TMD pain. Differences in pain modulation have been reported in both women and men with temporomandibular disorders compared to healthy controls. In a small case-control study, women with TMD demonstrated lower pain tolerance than control subjects [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Functional brain imaging studies in people with TMD demonstrated increased activation of the somatosensory cortex, anterior cingulate and prefrontal cortex, and decreased thalamic activation [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/26\">",
"     26",
"    </a>",
"    ]. This pattern of neural activation is similar to activation in patients with other chronic pain disorders and may be related to abnormal pain processing in the trigeminal system. In particular, muscle pain disorders appear to have little, if any, abnormality of the muscles or peripheral tissues and may represent a central sensitization pain producing process [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic marker studies suggest that certain gene polymorphisms (eg, the catechol-O-methyl transferase [",
"    <em>",
"     COMT",
"    </em>",
"    ] gene) might be associated with differences in pain response and processing in patients with chronic TMD [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1713552464\">",
"    <span class=\"h2\">",
"     Behavioral factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies support an association between chronic TMD and psychiatric illnesses, including anxiety, depression, post-traumatic stress disorder, or a history of abuse [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. A small observational study reported that individuals with depression had an increased risk of TMJ pain compared with euthymic individuals [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1144190397\">",
"    <span class=\"h2\">",
"     Head and cervical posture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor head and cervical posture has been thought to be a cause of TMD and pain because of the muscular attachments that connect the mandible and head and neck. A systematic review found that the studies of associations between",
"    <span class=\"nowrap\">",
"     cervical/head",
"    </span>",
"    posture and TMD were of poor methodology [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/33\">",
"     33",
"    </a>",
"    ]. The association, if any, is still unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242703351\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three distinct elements contributing to temporomandibular disorder (TMD) are muscle dysfunction, specific problems with the temporomandibular joint, and cervical spinal dysfunction [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, symptoms are characterized by acute or chronic musculoskeletal pain triggered by jaw motion, dysfunction of the masticatory system, temporomandibular joint (TMJ) tenderness, and neck stiffness and pain. The anatomic source of pain can originate from the TMJ or the muscles of mastication that attach to the TMJ or move the jaw (",
"    <a class=\"graphic graphic_figure graphicRef57658 \" href=\"UTD.htm?14/54/15206\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a retrospective study of 4528 patients with TMD, the most common presenting signs and symptoms were [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/35\">",
"     35",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain (96.1 percent)",
"     </li>",
"     <li>",
"      Ear discomfort or dysfunction (82.4 percent)",
"     </li>",
"     <li>",
"      Headache (79.3 percent)",
"     </li>",
"     <li>",
"      TMJ discomfort or dysfunction (75.0 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104372631\">",
"    <span class=\"h2\">",
"     Facial pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain of TMD is unilateral facial pain, described as a dull, constant ache that waxes and wanes in intensity. The pain can radiate to the ear, temporal and periorbital regions, the angle of the mandible, and, frequently, the posterior neck. It can be present daily or intermittently, with many patients having periods when they do not have any pain. Patients can also have episodes of sharper, more intense, pain. Patients may describe this as &ldquo;sinus&rdquo; pain in the zygomatic or orbital area [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/34\">",
"     34",
"    </a>",
"    ]. Pain is worsened by jaw motion.",
"   </p>",
"   <p>",
"    Clenching, acute or chronic stress, loss of posterior teeth combined with daytime tooth clenching can create muscle trigger points or muscle fatigue. This is noted by the patient after meals and reported as a &ldquo;heavy and tired feeling&rdquo; in the jaw muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165514831\">",
"    <span class=\"h2\">",
"     Ear pain, stuffiness, and tinnitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ear pain, stuffiness, and tinnitus may have a musculoskeletal etiology [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/36\">",
"     36",
"    </a>",
"    ]. The trigeminal nerve that innervates the medial pterygoid muscles (which help stabilize the mandible during movement) also innervates the middle ear muscles. The tensor tympani and tensor palati also wrap around the hamulus notch of the maxilla, so TMD can present with otologic symptoms (",
"    <a class=\"graphic graphic_figure graphicRef54135 \" href=\"UTD.htm?36/5/36949\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tinnitus can also have a peripheral musculoskeletal etiology [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/37\">",
"     37",
"    </a>",
"    ]. Specifically, cervical and mandibular postural factors (eg, repetitive postures) that appear to affect the normal musculoskeletal mechanics have been noted in people with tinnitus. Somatic tinnitus has been shown to be affected by altering maxillomandibular relationships and with manual physical therapy to the cervical paraspinal musculature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unilateral sharp, jabbing ear pain with mandibular movement is reported frequently in patients who have an internal derangement of the ipsilateral TMJ. Ear pain and symptoms in the absence of positive otologic findings are among the most common reasons to evaluate for the presence of TMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165514956\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical headache associated with TMD is described as unilateral ear or preauricular pain that radiates to the jaw, temple, or neck. The pain is deep, dull, continuous, moderate in intensity, aching, and usually worse in the morning [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. The headache can also be bilateral, originating from postural muscles or the muscles of mastication. Pain exacerbations are often provoked by use of the affected muscles. Morning headaches may be caused by nocturnal bruxism or sleep disorders [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/3\">",
"     3",
"    </a>",
"    ], while increasing pain during the day may be related to masticatory muscle use or head posture [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some individuals present with headache without being aware of having a TMJ problem [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. In addition to the typical headache, other manifestations of TMD-related headache include: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Front of head",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      Patients complaining of pain in the front of the head often refer to it as sinus headache. There is usually accompanying pressure along the upper front teeth, bridge of the nose, and behind the eyes. &ldquo;Sinus headaches&rdquo; are generally not due to sinus disease, but are a primary headache disorder. Posterior neck muscle contractions or frontalis muscle tension can also cause band-like pains in the front of the head.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Side of head",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      Temporal headaches are primarily caused by muscle contraction and spasm of the temporalis muscle. The anterior temporalis muscle fibers bring the lower jaw up and forward. The middle and posterior fibers swing the jaw to full closure and retract the mandible. Teeth clenching, grinding, or biting on objects while the jaw is in an anteriorly displaced position causes pain in the anterior temporalis group. Individuals who work at desk jobs where the head is kept forward and down tend to clench and grind their teeth in this forward position, with gravity affecting the mandible. Headaches in the temporal area are also brought on by chronic pencil or pen biting, pipe smoking, or gum chewing. Bruxism during sleep or in a posterior position tires the middle and posterior group of temporalis fibers, causing pain in a more posterior temporal location. Generally, the temporalis muscle is affected by any dysfunction of the lower jaw [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/47\">",
"       47",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Back of head",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      Deep, dull, constant pain in the back of the head is usually caused by spasms of the trapezius and sternocleidomastoid muscles. When tensed or strained, these muscles pull on their bony attachments to the skull in the occiput and mastoid areas, leading to soreness in the bone and pain radiating to the back of the head and neck.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1144190418\">",
"    <span class=\"h2\">",
"     Jaw and TMJ dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaw and TMJ dysfunction manifests as decreased mandibular range of motion, clicking or popping noises with jaw function, involuntary jaw clenching or teeth grinding, or jaw deviation to the affected side. Jaw locking can be present but is atypical; it is described as the inability to open the mouth, but sometimes inability to close the mouth. Symptoms are usually worse in the morning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165515139\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165515147\">",
"    <span class=\"h3\">",
"     Neck pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck stiffness and pain is a common TMD symptom [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Trauma, bad posture, and musculoskeletal tension in the cervical area create pain, stiffness, and trigger points in the muscles of the head and neck. Loss of vertical dimension of the teeth and a deep bite can also affect cervical function, leading to neck stiffness, pain, and reduced range of motion [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372548458\">",
"    <span class=\"h3\">",
"     Eye pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orbital and periorbital pain symptoms in patients with TMD are often described as unilateral, constant, and &ldquo;boring&rdquo; [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/34,52-54\">",
"     34,52-54",
"    </a>",
"    ]. Patients with a history of trauma, chronic upper cervical vertebral subluxations, or nerve root impingements in the occiput or atlantoaxial region may present with eye pain. In addition, entrapment of the greater occipital nerve at the occiput level can also produce this type of pain, which is often diagnosed as occipital neuralgia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31509?source=see_link\">",
"     \"Occipital neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165515166\">",
"    <span class=\"h3\">",
"     Arm and back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with TMD may also present with shoulder pain that radiates down the arm. The pain may be accompanied by tingling or numbness. Arm or back pain associated with TMD can be attributed to a number of causes, including rotator cuff injury, nerve impingement of the brachial plexus, vertebral subluxations, or thoracic outlet syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link\">",
"     \"Overview of thoracic outlet syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H5#H5\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Cervical spinal column injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372548466\">",
"    <span class=\"h3\">",
"     Dizziness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with TMD may have dizziness that is associated with ear pain and stuffiness or cervical muscle strain and tension. Other causes of dizziness should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=see_link\">",
"     \"Approach to the patient with dizziness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26338311\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of temporomandibular disorders (TMD) is based on the history and findings on physical examination. A history of facial pain, pain with jaw function, limitation of jaw movement, and cracking or popping noise with jaw function are all typical with TMD. Physical examination findings that characterize TMD are: facial or jaw pain, limited mouth opening, and TMJ noises with function. &nbsp;",
"   </p>",
"   <p>",
"    Imaging studies may, in some cases, clarify the diagnosis. Imaging is generally used when there may be an articular disc derangement disorder, an",
"    <span class=\"nowrap\">",
"     arthropathy/arthridity,",
"    </span>",
"    or some sort of tumor. Typically, plain film panoramic radiography of the jaws is used as initial imaging, with maxillofacial cone-beam CT scanning and MRI of the temporomandibular joints as additional imaging depending on the rest of the diagnostic evaluation findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372548282\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals will present most often with complaints of facial pain, headache, ear symptoms, TMJ pain, or symptoms of jaw dysfunction. Individuals need to be asked about history of any TMJ or jaw trauma. The history includes questions about sleep habits and position, symptoms of nighttime bruxism (jaw soreness or headache in the morning), and any past or present use of mouth orthotics. Since behavioral and occupational factors play a role in TMD, a thorough history includes questions about the patient&rsquo;s occupation, hobbies, and personal habits, such as usual posture, nail biting, or frequent gum chewing. A basic screening for symptoms of depression or anxiety is also necessary, including questions about any recent stressful events. (See",
"    <a class=\"local\" href=\"#H242703351\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1713551742\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372548290\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following physical examination findings, taken in conjunction with compelling symptoms of TMD, support the diagnosis of TMD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Abnormal mandibular movements",
"      </strong>",
"      &mdash; Observe opening and closing of the mouth, with attention to any jaw or dental protrusion. Check to see if the upper teeth and lower teeth are aligned. Look for jaw deviation on opening and closing. Abnormal mandibular movements have an overall sensitivity of 4 to 92 percent and specificity for TMD of 8 to 97 percent [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Decreased range of motion of temporomandibular joint (TMJ)",
"      </strong>",
"      &mdash; Measure functional range of motion of jaw opening. Normal functional opening is 35 to 55 mm [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/17,56\">",
"       17,56",
"      </a>",
"      ]. The functional opening in patients with TMD is typically less than 25 mm and very often associated with pain on active movement and passive stretching.",
"     </li>",
"     <li>",
"      <strong>",
"       Muscles of mastication tenderness",
"      </strong>",
"      &mdash; Palpate the TMJ and muscles of mastication (masseter, temporalis, medial and lateral pterygoids), assessing for muscle tenderness, joint crepitus, or jaw click during opening and closing. Note, however, that joint crepitus or jaw click has an overall sensitivity of 2 to 89 percent and specificity for TMD of 14 to 97 percent [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/55\">",
"       55",
"      </a>",
"      ]. Pain elicited on palpation of the TMJ and muscles of mastication has an overall sensitivity of 17 to 100 percent and specificity for TMD of 2 to 91 percent.",
"     </li>",
"     <li>",
"      <strong>",
"       Pain with dynamic loading",
"      </strong>",
"      &mdash; To elicit pain with dynamic loading, have patient bite on a cotton roll or grasp the mandible on both sides, pressing down and back to compress the TMJ bilaterally [",
"      <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Bruxism",
"      </strong>",
"      &mdash; Examine the oral cavity and dentition, looking for signs of tooth wear. This exam may be done by the patient&rsquo;s dentist.",
"     </li>",
"     <li>",
"      <strong>",
"       Postural asymmetry",
"      </strong>",
"      &mdash; Observe upper body posture, assessing for slouching or a preference to lean to one side.",
"     </li>",
"     <li>",
"      <strong>",
"       Neck and shoulder muscle tenderness",
"      </strong>",
"      &mdash; Inspect and palpate the muscles of the anterior and posterior neck and shoulders, assessing for muscle tension, tenderness, or trigger points.",
"     </li>",
"     <li>",
"      <strong>",
"       Normal cranial nerves examination",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7810856\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the temporomandibular joint and the maxillofacial skeleton in patients with suspected TMD remains controversial. In some cases, radiographic imaging can help confirm the diagnosis. The most common and helpful diagnostic study is imaging with panoramic radiography of the jaws. This is considered a useful initial imaging modality to evaluate the bone structure, teeth, sinuses, and TMJ shape.",
"   </p>",
"   <p>",
"    Further imaging is helpful in patients who may have anatomic abnormalities that can complicate diagnosis (eg, patients with articular disc derangements, rheumatoid arthritis, osteoarthritis, tumor). Maxillofacial cone-beam computerized tomography (CT) scans and magnetic resonance imaging (MRI) of TMJ are obtained in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal panoramic jaw radiograph (eg, changes in mandibular condyle or glenoid fossa morphology or position, degenerative changes)",
"     </li>",
"     <li>",
"      Physical exam findings that are atypical (eg, extreme pain, jaw locking)",
"     </li>",
"     <li>",
"      Abnormal cranial nerve examination",
"     </li>",
"     <li>",
"      History of TMJ surgery &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3691165\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional diagnostic studies are local trigeminal nerve blocks, muscle trigger point injections (anesthetic",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    corticosteroid), botulinum toxin injections, and maxillomandibular skeletal analysis using dental models or computerized cephalometric radiographic analysis. Whether or not these tests are used is assessed on an individual patient basis. Results are often difficult to interpret because of confounding factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372548275\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although temporomandibular disorders (TMD) are a common cause of craniofacial pain, it is important to exclude other potentially serious disorders. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1308013954\">",
"    <span class=\"h2\">",
"     Facial pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illnesses with overlapping symptoms with those of TMD can be caused by a variety of dental and nondental disorders (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=see_link\">",
"     \"Overview of craniofacial pain\"",
"    </a>",
"    ). Dental disorders that produce facial pain similar to TMD include caries, periodontal disease, malocclusion, and loss of posterior teeth support. Nondental disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders of the facial structures (eg, parotid glands) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22758?source=see_link\">",
"       \"Suppurative parotitis in adults\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Trigeminal neuralgia &mdash; Trigeminal neuralgia pain is described as &ldquo;stabbing&rdquo; and can be accompanied by facial muscle spasms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"       \"Trigeminal neuralgia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Head and neck cancer pain (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=see_link\">",
"       \"Overview of head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glossopharyngeal neuralgia &mdash; Glossopharyngeal neuralgia is characterized by paroxysmal, severe, stabbing pain involving the ear, tonsillar fossa, base of the tongue, or beneath the angle of the jaw. Typical triggers include chewing, swallowing, coughing, speaking, yawning, certain tastes, or touching the neck or external auditory canal (rarely the pre- or post-auricular areas).",
"     </li>",
"     <li>",
"      Postherpetic neuralgia &mdash; Postherpetic neuralgia pain is often described as &ldquo;burning.&rdquo; Patients often have areas of anesthesia, as well as deficits of thermal, tactile, pinprick, and vibration sensation within the affected dermatomes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"       \"Postherpetic neuralgia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carotidynia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of craniofacial pain\", section on 'Carotidynia'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Sinusitis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"       \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1308013961\">",
"    <span class=\"h2\">",
"     Otologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of tinnitus need to be considered (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    ). Other causes of ear pain or stuffiness include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute otitis media (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link\">",
"       \"Acute otitis media in adults (suppurative and serous)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eustachian tube dysfunction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8458?source=see_link\">",
"       \"Eustachian tube dysfunction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ear barotrauma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"       \"Ear barotrauma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Middle ear injuries (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link\">",
"       \"Evaluation and management of middle ear trauma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1308013968\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;In TMD patients presenting with headache, other causes of headache, such as stroke, temporal arteritis, migraine, and cluster headache must be considered before making a diagnosis of TMD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some stroke subtypes are accompanied by headache; however, stroke can be distinguished from TMD-related headache by other characteristic features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood and serum inflammatory markers (eg, elevated erythrocyte sedimentation rate) may distinguish temporal arteritis from TMD in a patient presenting with unilateral temporal headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Migraine headaches typically progress through four phases: prodromal, migraine aura, the headache, and the postdromal phase. Although migraine headaches are typically unilateral, like TMD headaches, the former are often accompanied by nausea, vomiting, and phono- or photophobia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cluster headaches, unlike TMD-related headaches, are characterized by unilateral autonomic symptoms, such as ptosis, miosis, lacrimation, conjunctival injection, rhinorrhea, and nasal congestion, ipsilateral to the pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1308013975\">",
"    <span class=\"h2\">",
"     Jaw and temporomandibular joint (TMJ) dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaw and TMJ dysfunction caused by TMD must be distinguished from TMJ dislocation and other causes of mandibular dysfunction. TMJ dislocation is painful and frightening for the patient. On examination, the patient is unable to close the mouth and there is excessive salivation. A depression may be noted in the preauricular area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26340?source=see_link\">",
"     \"Reduction of temporomandibular joint (TMJ) dislocation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link\">",
"     \"Facial trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26338376\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few high-quality randomized trials assessing the treatment of temporomandibular disorders (TMD) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/57-68\">",
"     57-68",
"    </a>",
"    ]. Our management approach outlined below is based upon the limited available data and clinical expertise. We suggest a combined approach using nonpharmacologic (patient education and self-care,) and pharmacologic therapy, when indicated, which often alleviates the symptoms completely or reduces the impact on the patient. Biobehavioral management or occlusal splints may be indicated in certain patients. Muscle trigger point injections and intra-articular temporomandibular joint (TMJ) injections may also have a therapeutic role in some cases.",
"   </p>",
"   <p>",
"    Surgery is only considered if there is persistent pain and functional limitations in patients with structural anatomic pathology or TMJ intra-articular disorders that do not respond to a reasonable course (at least three to six months) of non-surgical interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6356317\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165515331\">",
"    <span class=\"h3\">",
"     Nonpharmacologic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment typically includes patient education (about avoiding triggers, nature of the condition, and rationale for treatment) and self-care aimed at improving pain and function from TMD [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/69\">",
"     69",
"    </a>",
"    ]. Individuals with TMD are counseled on changing head posture, sleeping position, and parafunctional oral behaviors (eg, nail biting, pen chewing) if these factors contribute to their TMD symptoms. Patients usually respond to these noninvasive conservative treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6356701\">",
"    <span class=\"h4\">",
"     Self-care",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few trials assessing the benefits of self-care in improving TMD symptoms. In one trial, 117 patients were randomly assigned to usual care (patient education, physical therapy, medications, and occlusal splints) versus a tailored self-care program (education, guided reading with feedback, relaxation and stress management training, self-monitoring of symptoms, individualized TMD self-care plan, supervised reinforcement of jaw exercises, and maintenance and relapse prevention) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/69\">",
"     69",
"    </a>",
"    ]. After four months, there was a significantly greater decrease in mean pain intensity score (0 to 10 scale) from baseline in the self-care group (-2.5 versus -1.1 points in the usual care group) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/69\">",
"     69",
"    </a>",
"    ]. At one year, there were no differences between the two groups. Although this decrease is of uncertain clinical significance, given the lack of harm from this intervention, we suggest providing all TMD patients with a tailored patient self-care program. This can include referral to TMD centers, where available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611222194\">",
"    <span class=\"h4\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biobehavioral management and occlusal splints can be useful adjunctive treatments in certain individuals with TMD. We do not refer patients for routine physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88680930\">",
"    <span class=\"h5\">",
"     Biobehavioral management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biobehavioral management can be considered as adjunctive therapy in patients with comorbid anxiety or depression, but we do not typically refer all patients with TMD for routine biobehavioral management. For patients with concurrent depression or anxiety, treating their psychiatric conditions is also important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some trials, biobehavioral management (eg, biofeedback, cognitive behavioral therapy [CBT]) improved TMD symptoms [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In a meta-analysis of 17 trials evaluating psychosocial interventions (eg, CBT, biofeedback) compared with other forms of treatment (pharmacologic, physical therapy), there was a small but significant improvement in long-term pain intensity (seven trials) and depression (six trials), favoring psychosocial interventions [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/72\">",
"     72",
"    </a>",
"    ]. However, the meta-analysis was limited by the small number of high-quality trials and the risk of bias. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88680923\">",
"    <span class=\"h5\">",
"     Occlusal splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with TMD pain that is clearly attributable to bruxism, or who have signs of worn tooth enamel, we refer to a dentist who can evaluate for fitting an occlusal splint as an adjunct to the above interventions. Patients in which the diagnosis is unclear (bruxism versus a sleep disorder) should be evaluated with a sleep study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link\">",
"     \"Classification of sleep disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TMD patients with nighttime bruxism were traditionally fitted for occlusal splints (removable, usually rigid dental plates that reduce tooth grinding) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. A 2012 meta-analysis of 11 studies showed that the use of splints reduced pain from TMD (mean change on the 100 mm visual analog scale = -11.5 mm, 95% CI -16.5 to -6.6) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/75\">",
"     75",
"    </a>",
"    ]. In contrast, a subsequent small randomized trial showed that education about TMD and self-care was slightly more effective at reducing TMD muscle pain after three months than use of an occlusal splint without education (relative change in visual analog pain scale -11 versus +2.5) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/76\">",
"     76",
"    </a>",
"    ]. Pain-free mouth opening, headache, and pain during chewing were not significantly different between the two treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88681031\">",
"    <span class=\"h5\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical therapy is a common component of TMD management. However, given the lack of data on its efficacy, we do not refer TMD patients for routine physical therapy. A 2006 systematic review of the efficacy of physical therapy interventions for TMD showed a paucity of studies with strong methodology [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/77\">",
"     77",
"    </a>",
"    ]. In a subsequent trial, 49 patients with TMD (from anterior disc displacement without reduction) were randomly assigned to education only versus education with nine sessions of physical therapy [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/78\">",
"     78",
"    </a>",
"    ]. After 3, 6, 12, 26, and 52 weeks, there was equal improvement in both groups for pain and functional scores, without additional positive benefit of physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1332354260\">",
"    <span class=\"h3\">",
"     Pharmacologic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, pharmacotherapy (nonsteroidal antiinflammatory drugs [NSAIDS], tricyclic antidepressants, muscle relaxants), may be helpful for acute treatment [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/60-63,65,79\">",
"     60-63,65,79",
"    </a>",
"    ]. These agents have some utility in many chronic pain disorders, particularly myofascial pain disorders, however, there is insufficient evidence for their efficacy in treating chronic TMD and a scarcity of high-quality randomized controlled trials evaluating their efficacy [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/80\">",
"     80",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    We typically suggest a brief 10 to 14 day course of NSAIDS (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    250 to 500 mg twice daily). The longer-acting NSAIDs are generally well tolerated with good patient compliance [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/80\">",
"     80",
"    </a>",
"    ]. For patients with pain on palpation of the muscles of mastication, in addition to NSAIDS, we typically prescribe a short course of a centrally-acting skeletal muscle relaxant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    10 mg at bedtime or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/61/41940?source=see_link\">",
"     metaxalone",
"    </a>",
"    800 mg three times a day if daytime use is preferred). In a small trial (n = 41) cyclobenzaprine (10",
"    <span class=\"nowrap\">",
"     mg/night",
"    </span>",
"    for three weeks) compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    and placebo showed a statistically-significant improvement in average intensity of jaw pain on awakening [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If NSAIDs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muscle relaxants are not effective after two to three weeks, then adding a tricyclic antidepressant for pain control has been shown to be effective, especially when the TMD is part of generalized chronic muscular pain [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/17\">",
"     17",
"    </a>",
"    ]. A small trial of 12 female TMD patients demonstrated a significant decrease in pain, measured by a visual analog scale, in the group treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 14 days, compared to placebo (75 versus 28 percent, respectively) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/79\">",
"     79",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    We typically prescribe a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    for up to four months, and then taper to the lowest effective maintenance dose. Nortriptyline and doxepin seem to be better tolerated with fewer side effects than other tricyclic antidepressants, again increasing patient compliance. If patients with TMD have been pain-free for several months, then reevaluate the need for treatment with the tricyclic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link&amp;anchor=H9187574#H9187574\">",
"     \"Overview of the treatment of chronic pain\", section on 'Tricyclic antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-acting benzodiazepines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    2.5 to 5.0 mg, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    0.5 mg), given at night, can be used in the short-term (two to three weeks) for the acute treatment of severe TMD symptoms. When stopping benzodiazepine treatment, the dose needs to be tapered gradually over two weeks. In one trial, 39 patients with orofacial muscle pain were randomly assigned to diazepam (average 17 mg daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (average 2400 mg daily), diazepam plus ibuprofen, or placebo [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/63\">",
"     63",
"    </a>",
"    ]. After four weeks, pain intensity (visual analog scale) decreased in all groups. There was no difference among the four groups. All three non-placebo groups had improvement in depression symptoms. Benzodiazepines should be avoided in patients with a history of alcohol or drug addiction.",
"   </p>",
"   <p>",
"    There is no solid evidence to support the long-term use of opioid analgesics and benzodiazepines in the treatment of TMD pain and their long-term use should be avoided [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/61,80,81\">",
"     61,80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611222368\">",
"    <span class=\"h3\">",
"     Specific populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special considerations are needed in a few TMD patient populations.",
"   </p>",
"   <p>",
"    In patients with osteoarthritis (degenerative joint disease), the majority can be treated with the noninvasive techniques outlined above. However, in the acute phase, patients may require intra-articular injection of a long-acting corticosteroid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    ) or hyaluronic acid. There are few trials examining the efficacy of this approach, but some patients note a reduction in pain for as long as six months. Neither corticosteroids nor hyaluronic acid are recommended for long-term use. These injection treatments are generally reserved for older patients and are limited to two or three injections separated by four to six weeks.",
"   </p>",
"   <p>",
"    For patients with rheumatoid arthritis, in addition to the standard initial management for TMD, they should be maximally treated for their rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165515339\">",
"    <span class=\"h2\">",
"     Refractory TMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of TMD can be treated effectively by noninvasive, nonsurgical interventions. For patients who do not respond to initial therapy, additional management options may include: surgery, trigger point muscle injections, botulinum toxin injections, intra-articular injections (local anesthesia",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    corticosteroid or hyaluronic acid), and complementary and alternative therapies (eg, acupuncture, herbs and supplements, manual therapies) [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. These treatments have not been tested in large, rigorous, placebo-controlled trials.",
"   </p>",
"   <p>",
"    Patients with jaw locking, especially when long standing, will most often require interventions such as intra-articular corticosteroid injections or surgical interventions, such as arthrocentesis or arthroscopy. In patients with osteoarthritis of the TMJ who have refractory symptoms, surgery may be indicated to remove the loose fragments of bone (&ldquo;joint mice&rdquo;) and reshape the condyle. If medical management is not effective in patients with rheumatoid arthritis, then surgical treatment may be necessary, similar to other joints in the body.",
"   </p>",
"   <p>",
"    We suggest surgery for the management of refractory TMD in patients with persistent pain or functional limitations (jaw locking severe enough to interfere with activities of daily living), who have structural anatomic pathology (eg, internal derangement of the",
"    <span class=\"nowrap\">",
"     TMJ/articular",
"    </span>",
"    disc complex) causing symptoms that do not respond to more than three to six months of initial management. Surgical procedures include arthrocentesis, arthroscopy, open arthrotomy, and combined joint and reconstructive jaw procedures [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/84-88\">",
"     84-88",
"    </a>",
"    ]. The specific surgical intervention needed will depend on accurate diagnosis of the intra-articular disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1713551773\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with temporomandibular disorders (TMD) respond to treatment; however, a small minority of patients develops chronic TMD. The risk factors for development of persistent TMD are unknown. There may be an association between increased sympathetic tone and patients with chronic TMD [",
"    <a class=\"abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26338383\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporomandibular disorders (TMD) remain a frequent cause of visits to primary care clinicians and contribute to decreased quality of life and work absences. TMD generally affects more women than men, non-Hispanic Caucasians, and those between the ages of 18 and 44. There is an association between TMD and psychiatric comorbidities, which also impact the prognosis of TMD. (See",
"      <a class=\"local\" href=\"#H1713551742\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three distinct elements contributing to TMD are muscle dysfunction, specific problems with the temporomandibular joint (TMJ), and cervical spinal dysfunction. Although there is a structural component to TMD, biologic, behavioral, environmental, and cognitive factors all play a role in the development of symptoms. These can include a history of TMJ trauma, differences in pain perception, comorbid mood symptoms, and head and neck posture. (See",
"      <a class=\"local\" href=\"#H1713551750\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presenting signs and symptoms of TMD are acute or chronic facial pain triggered by jaw motion, dysfunction of the masticatory system, TMJ tenderness, and neck stiffness and pain. Headache and ear discomfort are also common presenting symptoms. (See",
"      <a class=\"local\" href=\"#H242703351\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of TMD is based on the history and findings on physical examination. A history of facial pain, pain with jaw function, limitation of jaw movement, and cracking or popping noise with jaw function are all typical of TMD. Physical examination findings that characterize TMD are: facial or jaw tenderness, limited mouth opening, and TMJ noises with function. (See",
"      <a class=\"local\" href=\"#H26338311\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of TMD is extensive. Other causes of facial pain, ear discomfort, headache, and jaw and TMJ dysfunction need to be excluded. (See",
"      <a class=\"local\" href=\"#H1372548275\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with TMD require a combined approach using nonpharmacologic (patient education and self-care) and pharmacologic therapy, when indicated, which often alleviates the symptoms completely or reduces their impact. In addition, patients with comorbid mood disorders need to be identified and treated for their psychiatric illness. (See",
"      <a class=\"local\" href=\"#H26338376\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the initial nonpharmacologic management of adults with TMD pain, we suggest patient education and self-care (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1165515331\">",
"       'Nonpharmacologic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biobehavioral management and occlusal splints can be useful adjunctive treatments in certain individuals with TMD. We do not refer patients for routine physical therapy. (See",
"      <a class=\"local\" href=\"#H611222194\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the initial pharmacologic management of adults with TMD pain, we suggest a 10&ndash; to 14-day course of a nonsteroidal anti-inflammatory drug (NSAID) as an adjunct to nonpharmacologic management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with pain on palpation of the muscles of mastication, we suggest a 10&ndash; to 14-day course of a muscle relaxant (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"       cyclobenzaprine",
"      </a>",
"      ) used in conjunction with the NSAID (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1332354260\">",
"       'Pharmacologic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If NSAIDS and muscle relaxants are not effective, we suggest adding a tricyclic antidepressant for up to four months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Long-term use of opioid analgesics and benzodiazepines should be avoided. (See",
"      <a class=\"local\" href=\"#H1332354260\">",
"       'Pharmacologic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the management of refractory TMD in patients with persistent pain or functional limitations who have structural pathology causing symptoms that do not respond to more than three to six months of initial management, we suggest surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgical procedures include arthrocentesis, arthroscopy, open arthrotomy, and combined joint and reconstructive jaw procedures. (See",
"      <a class=\"local\" href=\"#H1165515339\">",
"       'Refractory TMD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most individuals with TMD respond to treatment; however, a small portion of patients develop chronic TMD. The risk factors for development of persistent TMD are unknown. (See",
"      <a class=\"local\" href=\"#H1713551773\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35419230\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate would like to acknowledge Dr. Robert Sheon, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Oleson J. Cephalalgia. In: The International Classification of Headache Disorders, Blackwell Publishing, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/2\">",
"      Maixner W, Diatchenko L, Dubner R, et al. Orofacial pain prospective evaluation and risk assessment study--the OPPERA study. J Pain 2011; 12:T4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/3\">",
"      Macfarlane TV, Blinkhorn AS, Davies RM, et al. Oro-facial pain in the community: prevalence and associated impact. Community Dent Oral Epidemiol 2002; 30:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/4\">",
"      Von Korff M, Le Resche L, Dworkin SF. First onset of common pain symptoms: a prospective study of depression as a risk factor. Pain 1993; 55:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/5\">",
"      LeResche L. Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. Crit Rev Oral Biol Med 1997; 8:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/6\">",
"      Slade GD, Bair E, By K, et al. Study methods, recruitment, sociodemographic findings, and demographic representativeness in the OPPERA study. J Pain 2011; 12:T12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/7\">",
"      Ferrando M, Andreu Y, Gald&oacute;n MJ, et al. Psychological variables and temporomandibular disorders: distress, coping, and personality. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/8\">",
"      Manfredini D, di Poggio AB, Romagnoli M, et al. Mood spectrum in patients with different painful temporomandibular disorders. Cranio 2004; 22:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/9\">",
"      Dworkin SF, Sherman J, Mancl L, et al. Reliability, validity, and clinical utility of the research diagnostic criteria for Temporomandibular Disorders Axis II Scales: depression, non-specific physical symptoms, and graded chronic pain. J Orofac Pain 2002; 16:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/10\">",
"      Auerbach SM, Laskin DM, Frantsve LM, Orr T. Depression, pain, exposure to stressful life events, and long-term outcomes in temporomandibular disorder patients. J Oral Maxillofac Surg 2001; 59:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/11\">",
"      Turner JA, Dworkin SF, Mancl L, et al. The roles of beliefs, catastrophizing, and coping in the functioning of patients with temporomandibular disorders. Pain 2001; 92:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/12\">",
"      Campbell LC, Riley JL 3rd, Kashikar-Zuck S, et al. Somatic, affective, and pain characteristics of chronic TMD patients with sexual versus physical abuse histories. J Orofac Pain 2000; 14:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/13\">",
"      Fillingim RB, Maixner W, Sigurdsson A, Kincaid S. Sexual and physical abuse history in subjects with temporomandibular disorders: relationship to clinical variables, pain sensitivity, and psychologic factors. J Orofac Pain 1997; 11:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/14\">",
"      Garib BT, Qaradaxi SS. Temporomandibular joint problems and periodontal condition in rheumatoid arthritis patients in relation to their rheumatologic status. J Oral Maxillofac Surg 2011; 69:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/15\">",
"      Bracco P, Debernardi C, Piancino MG, et al. Evaluation of the stomatognathic system in patients with rheumatoid arthritis according to the research diagnostic criteria for temporomandibular disorders. Cranio 2010; 28:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/16\">",
"      Manfredini D, Lobbezoo F. Relationship between bruxism and temporomandibular disorders: a systematic review of literature from 1998 to 2008. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/17\">",
"      Scrivani SJ, Keith DA, Kaban LB. Temporomandibular disorders. N Engl J Med 2008; 359:2693.",
"     </a>",
"    </li>",
"    <li>",
"     Solberg WK. Epidemiology, Incidence and Prevalence of Temporomandibular Disorders: A Review. In: The President&rsquo;s Conference on the Examination, Diagnosis and Management of Temporomandibular Disorders, American Dental Association, Chicago 1983. p.30.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/19\">",
"      Milam SB, Zardeneta G, Schmitz JP. Oxidative stress and degenerative temporomandibular joint disease: a proposed hypothesis. J Oral Maxillofac Surg 1998; 56:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/20\">",
"      Milam SB, Schmitz JP. Molecular biology of temporomandibular joint disorders: proposed mechanisms of disease. J Oral Maxillofac Surg 1995; 53:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/21\">",
"      Zardeneta G, Milam SB, Schmitz JP. Presence of denatured hemoglobin deposits in diseased temporomandibular joints. J Oral Maxillofac Surg 1997; 55:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/22\">",
"      Israel HA, Langevin CJ, Singer MD, Behrman DA. The relationship between temporomandibular joint synovitis and adhesions: pathogenic mechanisms and clinical implications for surgical management. J Oral Maxillofac Surg 2006; 64:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/23\">",
"      Ratcliffe A, Israel HA, Saed-Nejad F, Diamond B. Proteoglycans in the synovial fluid of the temporomandibular joint as an indicator of changes in cartilage metabolism during primary and secondary osteoarthritis. J Oral Maxillofac Surg 1998; 56:204.",
"     </a>",
"    </li>",
"    <li>",
"     Macleod DK. Common problems of the teeth and oral cavity. In: Principles of Ambulatory Medicine, 6, Barker LR, Buron JR, Zieve PD, et al..  (Eds), Lippincott Williams &amp; Wilkins, 2003. p.1716-1717.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/25\">",
"      Bragdon EE, Light KC, Costello NL, et al. Group differences in pain modulation: pain-free women compared to pain-free men and to women with TMD. Pain 2002; 96:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/26\">",
"      de Leeuw R, Albuquerque R, Okeson J, Carlson C. The contribution of neuroimaging techniques to the understanding of supraspinal pain circuits: implications for orofacial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/27\">",
"      Shah JP, Gilliams EA. Uncovering the biochemical milieu of myofascial trigger points using in vivo microdialysis: an application of muscle pain concepts to myofascial pain syndrome. J Bodyw Mov Ther 2008; 12:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/28\">",
"      Peng YB, Kenshalo DR, Gracely RH. Periaqueductal gray-evoked dorsal root reflex is frequency dependent. Brain Res 2003; 976:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/29\">",
"      Nackley AG, Tan KS, Fecho K, et al. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 2007; 128:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/30\">",
"      Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006; 125:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/31\">",
"      Diatchenko L, Anderson AD, Slade GD, et al. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/32\">",
"      Kindler S, Samietz S, Houshmand M, et al. Depressive and anxiety symptoms as risk factors for temporomandibular joint pain: a prospective cohort study in the general population. J Pain 2012; 13:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/33\">",
"      Olivo SA, Bravo J, Magee DJ, et al. The association between head and cervical posture and temporomandibular disorders: a systematic review. J Orofac Pain 2006; 20:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/34\">",
"      Mehta NR, Forgione AG, Rosenbaum RS, Holmberg R. \"TMJ\" triad of dysfunctions: a biologic basis of diagnosis and treatment. J Mass Dent Soc 1984; 33:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/35\">",
"      Cooper BC, Kleinberg I. Examination of a large patient population for the presence of symptoms and signs of temporomandibular disorders. Cranio 2007; 25:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/36\">",
"      Kuttila S, Kuttila M, Le Bell Y, et al. Characteristics of subjects with secondary otalgia. J Orofac Pain 2004; 18:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/37\">",
"      Ren YF, Isberg A. Tinnitus in patients with temporomandibular joint internal derangement. Cranio 1995; 13:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/38\">",
"      Kapur N, Kamel IR, Herlich A. Oral and craniofacial pain: diagnosis, pathophysiology, and treatment. Int Anesthesiol Clin 2003; 41:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/39\">",
"      Egermark I, Magnusson T, Carlsson GE. A 20-year follow-up of signs and symptoms of temporomandibular disorders and malocclusions in subjects with and without orthodontic treatment in childhood. Angle Orthod 2003; 73:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/40\">",
"      Sipil&auml; K, Zitting P, Siira P, et al. Temporomandibular disorders, occlusion, and neck pain in subjects with facial pain: a case-control study. Cranio 2002; 20:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/41\">",
"      Nassif NJ, Talic YF. Classic symptoms in temporomandibular disorder patients: a comparative study. Cranio 2001; 19:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/42\">",
"      Johansson A, Unell L, Carlsson GE, et al. Gender difference in symptoms related to temporomandibular disorders in a population of 50-year-old subjects. J Orofac Pain 2003; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/43\">",
"      Rasmussen P. Facial pain. IV. A prospective study of 1052 patients with a view of: precipitating factors, associated symptoms, objective psychiatric and neurological symptoms. Acta Neurochir (Wien) 1991; 108:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/44\">",
"      Glaros AG, Urban D, Locke J. Headache and temporomandibular disorders: evidence for diagnostic and behavioural overlap. Cephalalgia 2007; 27:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/45\">",
"      Gon&ccedil;alves DA, Bigal ME, Jales LC, et al. Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache 2010; 50:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/46\">",
"      Mitrirattanakul S, Merrill RL. Headache impact in patients with orofacial pain. J Am Dent Assoc 2006; 137:1267.",
"     </a>",
"    </li>",
"    <li>",
"     Mehta NR, Scrivani SJ, Correa L, Matheson JK. Sleep-Related Bruxism. In: Therapy in Sleep Medicine, Barkoukis TJ, Matheson JK, Ferber R, Doghramji K.  (Eds), Elsevier, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/48\">",
"      Fink M, W&auml;hling K, Stiesch-Scholz M, Tschernitschek H. The functional relationship between the craniomandibular system, cervical spine, and the sacroiliac joint: a preliminary investigation. Cranio 2003; 21:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/49\">",
"      Ciancaglini R, Testa M, Radaelli G. Association of neck pain with symptoms of temporomandibular dysfunction in the general adult population. Scand J Rehabil Med 1999; 31:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/50\">",
"      Svensson P, Wang K, Sessle BJ, Arendt-Nielsen L. Associations between pain and neuromuscular activity in the human jaw and neck muscles. Pain 2004; 109:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/51\">",
"      Chakfa AM, Mehta NR, Forgione AG, et al. The effect of stepwise increases in vertical dimension of occlusion on isometric strength of cervical flexors and deltoid muscles in nonsymptomatic females. Cranio 2002; 20:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/52\">",
"      Fernandez de las Pe&ntilde;as C, Cuadrado ML, Gerwin RD, Pareja JA. Referred pain from the trochlear region in tension-type headache: a myofascial trigger point from the superior oblique muscle. Headache 2005; 45:731.",
"     </a>",
"    </li>",
"    <li>",
"     Kalina R, Orcutt J. Ocular and periocular pain. In: The management of pain, Bonica JJ (Ed), Lee and Ferbiger, Philadelphia 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/54\">",
"      Curtis AW. Myofascial pain-dysfunction syndrome: the role of nonmasticatory muscles in 91 patients. Otolaryngol Head Neck Surg 1980; 88:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/55\">",
"      Reneker J, Paz J, Petrosino C, Cook C. Diagnostic accuracy of clinical tests and signs of temporomandibular joint disorders: a systematic review of the literature. J Orthop Sports Phys Ther 2011; 41:408.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/TMJ%20disorder.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/57\">",
"      Truelove E, Huggins KH, Mancl L, Dworkin SF. The efficacy of traditional, low-cost and nonsplint therapies for temporomandibular disorder: a randomized controlled trial. J Am Dent Assoc 2006; 137:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/58\">",
"      Dionne RA. Pharmacologic treatments for temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/59\">",
"      Ta LE, Dionne RA. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Pain 2004; 111:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/60\">",
"      List T, Axelsson S, Leijon G. Pharmacologic interventions in the treatment of temporomandibular disorders, atypical facial pain, and burning mouth syndrome. A qualitative systematic review. J Orofac Pain 2003; 17:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/61\">",
"      Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain 2002; 16:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/62\">",
"      Denucci DJ, Dionne RA, Dubner R. Identifying a neurobiologic basis for drug therapy in TMDs. J Am Dent Assoc 1996; 127:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/63\">",
"      Singer E, Dionne R. A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain. J Orofac Pain 1997; 11:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/64\">",
"      Dao TT, Lavigne GJ. Oral splints: the crutches for temporomandibular disorders and bruxism? Crit Rev Oral Biol Med 1998; 9:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/65\">",
"      Fricton J. Myogenous temporomandibular disorders: diagnostic and management considerations. Dent Clin North Am 2007; 51:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/66\">",
"      Fricton J. Current evidence providing clarity in management of temporomandibular disorders: summary of a systematic review of randomized clinical trials for intra-oral appliances and occlusal therapies. J Evid Based Dent Pract 2006; 6:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/67\">",
"      Dworkin SF. The case for incorporating biobehavioral treatment into TMD management. J Am Dent Assoc 1996; 127:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/68\">",
"      Crider A, Glaros AG, Gevirtz RN. Efficacy of biofeedback-based treatments for temporomandibular disorders. Appl Psychophysiol Biofeedback 2005; 30:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/69\">",
"      Dworkin SF, Huggins KH, Wilson L, et al. A randomized clinical trial using research diagnostic criteria for temporomandibular disorders-axis II to target clinic cases for a tailored self-care TMD treatment program. J Orofac Pain 2002; 16:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/70\">",
"      Dworkin SF, Turner JA, Mancl L, et al. A randomized clinical trial of a tailored comprehensive care treatment program for temporomandibular disorders. J Orofac Pain 2002; 16:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/71\">",
"      Stowell AW, Gatchel RJ, Wildenstein L. Cost-effectiveness of treatments for temporomandibular disorders: biopsychosocial intervention versus treatment as usual. J Am Dent Assoc 2007; 138:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/72\">",
"      Aggarwal VR, Lovell K, Peters S, et al. Psychosocial interventions for the management of chronic orofacial pain. Cochrane Database Syst Rev 2011; :CD008456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/73\">",
"      Wright EF, Syms CA 3rd, Bifano SL. Tinnitus, dizziness, and nonotologic otalgia improvement through temporomandibular disorder therapy. Mil Med 2000; 165:733.",
"     </a>",
"    </li>",
"    <li>",
"     file://tmj.org/site/content/splints (Accessed on November 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/75\">",
"      Ebrahim S, Montoya L, Busse JW, et al. The effectiveness of splint therapy in patients with temporomandibular disorders: a systematic review and meta-analysis. J Am Dent Assoc 2012; 143:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/76\">",
"      Michelotti A, Iodice G, Vollaro S, et al. Evaluation of the short-term effectiveness of education versus an occlusal splint for the treatment of myofascial pain of the jaw muscles. J Am Dent Assoc 2012; 143:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/77\">",
"      McNeely ML, Armijo Olivo S, Magee DJ. A systematic review of the effectiveness of physical therapy interventions for temporomandibular disorders. Phys Ther 2006; 86:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/78\">",
"      Craane B, Dijkstra PU, Stappaerts K, De Laat A. Randomized controlled trial on physical therapy for TMJ closed lock. J Dent Res 2012; 91:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/79\">",
"      Rizzatti-Barbosa CM, Nogueira MT, de Andrade ED, et al. Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders. Cranio 2003; 21:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/80\">",
"      Mujakperuo HR, Watson M, Morrison R, Macfarlane TV. Pharmacological interventions for pain in patients with temporomandibular disorders. Cochrane Database Syst Rev 2010; :CD004715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/81\">",
"      DeNucci DJ, Sobiski C, Dionne RA. Triazolam improves sleep but fails to alter pain in TMD patients. J Orofac Pain 1998; 12:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/82\">",
"      Ozkan F, Cak��r &Ouml;zkan N, Erkorkmaz U. Trigger point injection therapy in the management of myofascial temporomandibular pain. Agri 2011; 23:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/83\">",
"      Itoh K, Asai S, Ohyabu H, et al. Effects of trigger point acupuncture treatment on temporomandibular disorders: a preliminary randomized clinical trial. J Acupunct Meridian Stud 2012; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/84\">",
"      McCain JP, de la Rua H, Le Blanc WG. Correlation of clinical, radiographic, and arthroscopic findings in internal derangements of the TMJ. J Oral Maxillofac Surg 1989; 47:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/85\">",
"      Perrott DH, Alborzi A, Kaban LB, Helms CA. A prospective evaluation of the effectiveness of temporomandibular joint arthroscopy. J Oral Maxillofac Surg 1990; 48:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/86\">",
"      Nitzan DW, Dolwick MF, Heft MW. Arthroscopic lavage and lysis of the temporomandibular joint: a change in perspective. J Oral Maxillofac Surg 1990; 48:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/87\">",
"      McCain JP, Sanders B, Koslin MG, et al. Temporomandibular joint arthroscopy: a 6-year multicenter retrospective study of 4,831 joints. J Oral Maxillofac Surg 1992; 50:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/88\">",
"      Israel HA. Part I: The use of arthroscopic surgery for treatment of temporomandibular joint disorders. J Oral Maxillofac Surg 1999; 57:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./temporomandibular-disorders-in-adults/abstract/89\">",
"      Maixner W, Greenspan JD, Dubner R, et al. Potential autonomic risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. J Pain 2011; 12:T75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5629 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7194=[""].join("\n");
var outline_f7_1_7194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26338383\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26338276\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1713551742\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1713551750\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1713552171\">",
"      Joint trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1713552178\">",
"      Pain threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1713552464\">",
"      Behavioral factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1144190397\">",
"      Head and cervical posture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H242703351\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104372631\">",
"      Facial pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1165514831\">",
"      Ear pain, stuffiness, and tinnitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1165514956\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1144190418\">",
"      Jaw and TMJ dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1165515139\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1165515147\">",
"      - Neck pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1372548458\">",
"      - Eye pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1165515166\">",
"      - Arm and back pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1372548466\">",
"      - Dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26338311\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1372548282\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1372548290\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7810856\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3691165\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1372548275\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1308013954\">",
"      Facial pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1308013961\">",
"      Otologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1308013968\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1308013975\">",
"      Jaw and temporomandibular joint (TMJ) dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26338376\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6356317\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1165515331\">",
"      - Nonpharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6356701\">",
"      Self-care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H611222194\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H88680930\">",
"      - Biobehavioral management",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H88680923\">",
"      - Occlusal splints",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H88681031\">",
"      - Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1332354260\">",
"      - Pharmacologic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H611222368\">",
"      - Specific populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1165515339\">",
"      Refractory TMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1713551773\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26338383\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35419230\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/5629\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/5629|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/54/15206\" title=\"figure 1\">",
"      Temporomandibular joint TMJ anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/5/36949\" title=\"figure 2\">",
"      TMD nerves",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=related_link\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26727?source=related_link\">",
"      Etiology and diagnosis of tinnitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8458?source=related_link\">",
"      Eustachian tube dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=related_link\">",
"      Evaluation and management of middle ear trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=related_link\">",
"      Facial trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31509?source=related_link\">",
"      Occipital neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=related_link\">",
"      Overview of craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=related_link\">",
"      Overview of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=related_link\">",
"      Overview of thoracic outlet syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26340?source=related_link\">",
"      Reduction of temporomandibular joint (TMJ) dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=related_link\">",
"      Spinal column injuries in adults: Definitions, mechanisms, and radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22758?source=related_link\">",
"      Suppurative parotitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_1_7195="Classification of stem cells";
var content_f7_1_7195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of stem cells",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of cell",
"       </td>",
"       <td class=\"subtitle1\">",
"        Capable of producing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Example",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Totipotent",
"       </td>",
"       <td>",
"        Embryonic and extraembryonic tissues",
"       </td>",
"       <td>",
"        Within the first few cell divisions of the zygote",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pluripotent",
"       </td>",
"       <td>",
"        Any cell in the body including germ cells",
"       </td>",
"       <td>",
"        Inner cell mass of the blastocyst, embryonic stem cells, embryonic germ cells, induced pluripotent cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multipotent",
"       </td>",
"       <td>",
"        Restricted to a given germ layer or tissue cell type",
"       </td>",
"       <td>",
"        Hematopoietic stem cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unipotent",
"       </td>",
"       <td>",
"        Restricted to a specific cell lineage",
"       </td>",
"       <td>",
"        Germ cell stem cells",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7195=[""].join("\n");
var outline_f7_1_7195=null;
var title_f7_1_7196="WHO grade crit oral dysp";
var content_f7_1_7196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2005 WHO architectural and cytological criteria for grading oral epithelial dysplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Architectural criteria",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          1. Irregular epithelial stratification",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          2. Loss of polarity of basal cells",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          3. Drop-shaped rete ridges",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          4. Increased number of mitotic figures",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          5. Abnormally superficial mitoses",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          6. Premature keratinization in single cells",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          7. Keratin pearls within rete ridges",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cytological criteria",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          1. Abnormal variation in nuclear size",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          2. Abnormal variation in nuclear shape",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          3. Abnormal variation in cell size",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          4. Abnormal variation in cell shape",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          5. Increased nuclear-cytoplasmic ratio",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          6. Increased nuclear size",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          7. Atypical mitotic figures",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          8. Increased number and size of nucleoli",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          9. Hyperchromatism",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization Classification of Tumors: Pathology and Genetics: Head and Neck Tumors. Barnes, L, Everson, JW, Reichart, P, Sidransky, D, (eds). WHO Press (Switzerland) 2005; p.177. Copyright &copy;2005 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7196=[""].join("\n");
var outline_f7_1_7196=null;
var title_f7_1_7197="HEADSS assessment";
var content_f7_1_7197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The HEADSS acronym to screen for psychosocial problems",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          H(ome)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Household composition",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Family dynamics and relationships with adolescent",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Living/sleeping arrangements",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Guns in the home",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          E(ducation)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          School attendence/absences",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ever failed a grade? Grades compared with last year's?",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Attitude toward school",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Favorite and most difficult subjects",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Special educational needs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Goals: Vocational/technical school; college; career",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          A(ctivities)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Physical activity; exercise; hobbies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sports participation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Job",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Weapon carrying and fighting",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          D(rugs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cigarettes/smokeless tobacco: Age at first use; packs per day",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Alcohol and other drugs: Use at school or parties; use by friends, self; kind (beer, wine coolers); frequency; and quantity used",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          If yes, CAGE:",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Have you ever felt the need to Cut down?",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Have others Annoyed you by commenting on your use?",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Have you ever felt Guilty about your use?",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Have you ever needed an Eye-opener (eg, alcohol first thing in the morning)?",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          S(exuality)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sexual feelings: Opposite or same sex",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sexual intercourse: Age of first intercourse; number of lifetime and current partners; recent change in partners",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Contraceptive/sexually transmitted disease (STD) prevention",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          History of STDs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Prior pregnancies; prior abortions; ever fathered a child?",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          History of or current nonconsensual intimate physical contact/sex",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          S(uicide)/Depression",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Feelings about self: Positive and negative",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          History of depression or other mental health problems; prior suicidal thoughts; prior suicide attempts",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sleep problems: Difficulty getting to sleep; early waking",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Straub DM. Adolescent Medicine. In: The Harriet Lane Handbook, 15th Ed, Siberry GK, Iannone R (Eds), Mosby, St. Louis 2000. p.97. Copyright &copy; 2000 Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7197=[""].join("\n");
var outline_f7_1_7197=null;
var title_f7_1_7198="Fat content of oils";
var content_f7_1_7198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Fat content of oils",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When fats are needed for cooking, spreads, and other uses, oils with higher amounts of monounsaturated and/or polyunsaturated fatty acids should be used,&nbsp;such as canola oil and olive oil. Those oils that are higher in&nbsp;n-3 polyunsaturated fats (alpha-linoleic acid, ALA)&nbsp;such as walnut oil and, to a lesser extent, soybean oil are also beneficial. Linoleic acid (LA) is an n-6 polyunsaturated fatty acid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7198=[""].join("\n");
var outline_f7_1_7198=null;
var title_f7_1_7199="CBD obstruction OLT";
var content_f7_1_7199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common bile duct obstruction following liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography in a patient with jaundice after liver transplantation demonstrates almost complete obstruction of the bile duct anastomosis (large arrow) with minimal passage of contrast throughout the obstruction (small arrows). This lesion was successfully treated with balloon dilation",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_1_7199=[""].join("\n");
var outline_f7_1_7199=null;
